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Potentiated Hsp104 Variants Suppress The Toxicity Of Most Overexpressed
Dosage-Sensitive Yeast Genes
Abstract
Maintenance of optimal gene expression levels is critical for cell viability and homeostasis. However,
misregulation of gene expression can and regularly occur. One type of detrimental misregulation involves
overexpression of a single gene that can cause organismal death is dosage sensitivity, which is often due
to increased concentration of the protein encoded by the gene. Deleterious increases in the expression of
specific proteins are associated with various neurodegenerative diseases such as Parkinson’s and
Alzheimer’s Diseases as well as other cellular maladies including various cancers and Down Syndrome. In
yeast, it has been estimated that ~20% of genes are toxic when overexpressed. The physicochemical
properties and function of a protein seem to dictate whether it will be toxic upon overexpression.
However, the mechanism by which individual proteins become toxic when overexpressed is typically
unclear, which complicates the development of agents that counter toxicity of diverse dosage-sensitive
genes. The overarching goal of this thesis was to rationally engineer a ‘buffer’ that universally mitigates
the toxicity of dosage-sensitive genes.
To meet this goal, we turned to Hsp104, a hexameric, ring-shaped AAA+ ATPase and protein-remodeling
factor found in yeast, which protects yeast from toxicity associated with aggregated and misfolded
proteins induced by chemical, heat, or age-related stress. An engineered variant of Hsp104,
Hsp104A503S, displayed potentiated activity and suppressed proteotoxicity of various neurodegenerative
disease proteins, including TDP-43, FUS, and α-synuclein in yeast, whereas wild-type Hsp104 was
ineffective. Inspired by this striking activity, we determined whether Hsp104A503S could combat the
toxicity of diverse yeast dosage-sensitive genes. Surprisingly, Hsp104A503S suppressed the toxicity of
nearly 98% of dosage-sensitive genes tested, whereas wild-type Hsp104 rescued none. Expression of
Hsp70- or Hsp90-class chaperones also failed to suppress toxicity of the majority of dosage-sensitive
genes. To achieve this broad rescue of dosage-sensitive genes, Hsp104A503S required critical tyrosines
in pore-loops that engage substrate during protein remodeling and translocation across the central
channel of Hsp104. Moreover, ATPase activity at NBD1 or NBD2 was required for Hsp104A503S to
alleviate toxicity of dosage-sensitive genes. Rescue of toxicity by Hsp104A503S was not typically due to
decreases in toxic protein expression or disaggregation of amyloid. In addition, neither autophagy nor
proteasome activity was required for Hsp104A503S to rescue the toxicity of dosage-sensitive genes.
Rather, Hsp104A503S effectively prevented the formation of labile, SDS-soluble aggregates, which
correlated with alleviation of toxicity. With null mutants, we established that the intrinsic function of
several dosage-sensitive kinases and phosphatases was crucial for overexpression toxicity. In vitro
functional assays with Ppz1 (a dosage-sensitive protein phosphatase), indicated the phosphatase activity
was reduced by Hsp104A503S and not by Hsp104. Lastly, we demonstrated that Hsp104A503S
suppressed the toxicity of the potent oncogenic kinase, v-Src, in yeast, decreasing protein levels and
kinase activity in yeast. Thus, we suggest that in addition to preventing formation of labile, SDS-soluble
aggregates Hsp104A503S can also suppress dosage sensitivity by directly unfolding or otherwise
deactivating toxic protein such as Ppz1 and v-Src. These studies establish that potentiated proteinremodeling factors like Hsp104A503S can serve as a powerful buffer that mitigates the toxicity of nearly
all dosage-sensitive yeast genes.
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ABSTRACT

POTENTIATED HSP104 VARIANTS SUPPRESS THE TOXICITY OF MOST
OVEREXPRESSED DOSAGE-SENSITIVE YEAST GENES
Michael Yancey Soo
James Shorter, Ph.D.

Maintenance of optimal gene expression levels is critical for cell viability and
homeostasis. However, misregulation of gene expression can and regularly occur. One
type of detrimental misregulation involves overexpression of a single gene that can
cause organismal death is dosage sensitivity, which is often due to increased
concentration of the protein encoded by the gene. Deleterious increases in the
expression of specific proteins are associated with various neurodegenerative diseases
such as Parkinson’s and Alzheimer’s Diseases as well as other cellular maladies
including various cancers and Down Syndrome. In yeast, it has been estimated that
~20% of genes are toxic when overexpressed. The physicochemical properties and
function of a protein seem to dictate whether it will be toxic upon overexpression.
However, the mechanism by which individual proteins become toxic when
overexpressed is typically unclear, which complicates the development of agents that
counter toxicity of diverse dosage-sensitive genes. The overarching goal of this thesis
was to rationally engineer a ‘buffer’ that universally mitigates the toxicity of dosagesensitive genes.
To meet this goal, we turned to Hsp104, a hexameric, ring-shaped AAA+ ATPase
and protein-remodeling factor found in yeast, which protects yeast from toxicity
associated with aggregated and misfolded proteins induced by chemical, heat, or agevi

related stress. An engineered variant of Hsp104, Hsp104A503S, displayed potentiated
activity and suppressed proteotoxicity of various neurodegenerative disease proteins,
including TDP-43, FUS, and α-synuclein in yeast, whereas wild-type Hsp104 was
ineffective. Inspired by this striking activity, we determined whether Hsp104A503S could
combat the toxicity of diverse yeast dosage-sensitive genes. Surprisingly, Hsp104A503S
suppressed the toxicity of nearly 98% of dosage-sensitive genes tested, whereas wildtype Hsp104 rescued none. Expression of Hsp70- or Hsp90-class chaperones also
failed to suppress toxicity of the majority of dosage-sensitive genes. To achieve this
broad rescue of dosage-sensitive genes, Hsp104A503S required critical tyrosines in poreloops that engage substrate during protein remodeling and translocation across the
central channel of Hsp104. Moreover, ATPase activity at NBD1 or NBD2 was required
for Hsp104A503S to alleviate toxicity of dosage-sensitive genes. Rescue of toxicity by
Hsp104A503S was not typically due to decreases in toxic protein expression or
disaggregation of amyloid. In addition, neither autophagy nor proteasome activity was
required for Hsp104A503S to rescue the toxicity of dosage-sensitive genes. Rather,
Hsp104A503S effectively prevented the formation of labile, SDS-soluble aggregates, which
correlated with alleviation of toxicity. With null mutants, we established that the intrinsic
function of several dosage-sensitive kinases and phosphatases was crucial for
overexpression toxicity. In vitro functional assays with Ppz1 (a dosage-sensitive protein
phosphatase), indicated the phosphatase activity was reduced by Hsp104A503S and not
by Hsp104. Lastly, we demonstrated that Hsp104A503S suppressed the toxicity of the
potent oncogenic kinase, v-Src, in yeast, decreasing protein levels and kinase activity in
yeast. Thus, we suggest that in addition to preventing formation of labile, SDS-soluble
aggregates Hsp104A503S can also suppress dosage sensitivity by directly unfolding or
otherwise deactivating toxic protein such as Ppz1 and v-Src. These studies establish
vii

that potentiated protein-remodeling factors like Hsp104A503S can serve as a powerful
buffer that mitigates the toxicity of nearly all dosage-sensitive yeast genes.
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE
1.1 Proteins, Folding, and Misfolding
Proteins are essential building blocks of life and are required for almost every
process a living organism must undertake including growth, reproduction, responding to
stimuli or threats, and metabolizing nutrients. Other than water, no molecules are more
abundant in the cell than proteins (1) Proteins also exhibit incredible diversity. There are
about 30,000 protein-coding genes in the human genome, of which over 90% can be
alternatively spliced to yield hundreds of thousands of splice variants, each of which
could yield a unique protein if translated (2). As such, every organism must carefully
control every aspect of the process of protein production from transcribing DNA into
RNA, splicing pre-mRNA, and translating the transcript into polypeptide strings featuring
20 amino acids in various combinations, which provide the foundation for virtually every
protein on earth.
As proteins are synthesized by the ribosome, the different amino acids within the
polypeptide chain interact with each other to form stable interactions, folding the protein
into intricate three-dimensional structures to achieve the “native”, active confirmation.
However, some proteins are intrinsically disordered, featuring solvent-exposed regions
that do not form stable intramolecular interactions (3, 4). Even though the instructions for
how each protein folds into its native state are encoded in the primary amino acid
sequence, protein folding is a difficult, dynamic process and most proteins do not
instantaneously adopt their native structure but take a meandering route (5, 6). The first
step of protein folding is a hydrophobic collapse in which the hydrophobic residues
quickly bind to each other to form a molten globule that excludes water from the core of
1

the protein, which maximizes entropy of the water solvent (7-9). The protein then begins
to form secondary and tertiary structure, navigating towards the lowest energy
conformation, which can be an arduous process with many possible pathways and offtarget diversions for a protein to take through a potentially rugged energetic landscape to
reach the natively folded state (10) (Fig. 1). For large proteins with multiple domains, this
process can be especially difficult because as the protein folds, it forms many
intermediates that may not contribute to the final conformation. Moreover, in the
exceedingly crowded cytoplasm, the nascent polypeptide is bombarded with different
interacting binding partners such as lipids, nucleic acids, small molecules, and other
proteins (11).
Once the protein reaches the native state it constantly undergoes conformational
changes to execute its function. Protein functionality often demands a dynamic structure
that must explore different conformations to maximize activity. These various
conformations may only be marginally stable and place the protein at risk for misfolding
or aggregation (12). Moreover, thermodynamics dictate that a protein population at
equilibrium will feature proteins that are fully folded, partially folded, misfolded, and even
completely unfolded following a Boltzmann distribution where the lowest energy states
for the protein will have a higher probability of being occupied but all states from native
to completely disordered are populated (13). Furthermore, in the human proteome,
approximately half of all proteins are predicted to contain intrinsicially-disordered regions
that are permanently unfolded and nearly a quarter of total proteins are predicted to be
completely disordered (3).

2

Figure 1: Protein-folding energy landscape.
Protein folding takes place within a free energy landscape in which the protein must
navigate to reach the native folded state. Intermediates that become trapped in local
minima must overcome energy barriers to reach the final conformation. Cellular
chaperones in the cell help guide folding towards the native state, prevent aberrant
intermolecular interactions that can lead to amorphous aggregate or amyloid fibril
formation, and can disaggregate and unfold aggregated proteins to enable refolding to
the native state. (Adapted with permission from Elsevier, License Number:
3944940299836) (14)

Because protein folding is such a dynamic process, rife with obstacles, many
proteins require the aid of accessory proteins, termed chaperones, which aid in their
proper folding (Fig. 1) (15-18). The requirement for chaperones is especially acute if
proteins contain multiple domains requiring complex architectural organization. From the
moment a nascent polypeptide exits the ribosome, protein chaperones engage the
3

protein to facilitate folding (19-21). While small, single-domain proteins fold rapidly in
vivo and in test tubes, large multi-domain proteins often fold poorly in isolation,
generating partially folded intermediates and misfolded conformations, that often expose
hydrophobic regions that can promote self-association into aggregates (22). The
geometry of the ribosome and speed of protein translation dictates that folding can
typically not be completed until the entire sequence has emerged from the ribosomal
polypeptide exit channel (20, 21). To promote proper folding, emerging polypeptides are
immediately bound by molecular chaperones that associate with the ribosome, including
trigger factor in prokaryotes or nascent chain-associated complex (NAC) in eukaryotes
(20, 21, 23). These chaperones associate with the nascent protein and prevent
formation of aberrant inter- and intra-protein interactions until the polypeptide chain exits
the ribosome, thereby preventing improper folding. Chaperones of the classical Hsp70
system, DnaK and DnaJ in bacteria and Hsp70 and Hsp40 in eukaryotes, can also
associate with these nascent proteins while still emerging from the ribosome to facilitate
folding (24-26). In humans, there are over a dozen Hsp70 and Hsp40 genes, each family
member has their own substrate-binding preference and function in protein folding,
refolding, disaggregation, and transferring substrates to other downstream processes if
the client protein remain non-native (14, 25-27). These downstream processes could
include unfolding and refolding by the chaperonin system, GroEL and GroES in bacteria
or TRiC in eukaryotes (25, 26), the folding and maturation of clients by the Hsp90
system (28, 29), degradation by the ubiquitin proteasome system (30, 31), or
disaggregation of aggregated substrates by the Hsp100 or Hsp110 systems (32-35).
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1.2 Gene Overexpression and Its Causes
Cells have developed highly integrated systems for maintaining protein
homeostasis to ensure proper synthesis, folding, localization, and turnover in the
crowded cellular environment where macromolecular concentration can be as high as
300 mg/ml (most of which is protein) (11, 19). However, misregulation of gene
expression can and does occur. One example is the overexpress of a protein-coding
gene that can lead to an overabundance of the encoded protein. While many genes are
well-tolerated when expressed at high levels natively or are greatly induced in response
to stimuli or stress, aberrant overexpression of certain genes can lead to a wide variety
of human disease and disorders including Parkinson’s Disease (PD) (36-38), CharcotMarie-Tooth neuropathy (39), and a multitude of cancers (40, 41). This proteostatic
balance is so delicate that the increase in copy number of a single gene encoding αsynuclein, SNCA, can be the sole cause of some cases of PD (36). Aside from gene
duplication, increased gene dosage can be due to a variety of sources including
aneuploidy, chromosome translocation, activation of transcription factors, and defects in
protein degradation systems (42, 43).
1.2.1 Aneuploidy
Most eukaryotic organisms are diploid, possessing two homologous sets of
chromosomes, usually one from each parent. During cell division, new sets of
chromosomes must be synthesized from the existing chromosome and then segregated
equally between daughter cells during cell division. Aneuploidy is the condition when this
process is not accurately carried out, resulting in the abnormal increase or decrease in
the number of chromosomes. In most cases, the disruption to the cell caused by
5

aneuploidy is so severe that it leads to cells that are unable to grow, develop, or
continue through the cell cycle (44). The cause of the growth defect is likely due to a
confluence of factors including broad-spectrum transcriptome perturbations, effects on
expression of genes on other chromosomes, and an increased burden to the
transcription, translation, chaperone, and protein degradation systems (45).
Increases or decreases in the number of chromosomes can lead to altered
organismal fitness likely due to changes in gene expression. Microarray transcriptome
profiling in yeast lacking or containing an extra chromosome show that protein
expression levels are often correlated with copy number changes of that gene due to
aneuploidy (44, 46). In general, organisms are less able to accommodate losses in
whole chromosomes, due to decreases in the expression of essential proteins and
disruption of protein stoichiometry (47). However, gene dosage increases of most
individual genes, does not result in severe growth defects, rather loss of fitness in
organisms with extra chromosomes is likely due to the accumulation of multiple small
defects, where increased amounts of extra genetic material is correlated with the
decreases in proliferation (46). In the case of additional chromosomes, the additive
effect of many small changes in protein stoichiometry likely results in loss of fitness.
Organisms often attempt to compensate for increases in gene copy and subsequent
elevation of transcript levels by decreasing protein expression through suppression of
translation or increased degradation (48-51). This dependence on increased protein
degradation is supported by findings that show yeast with extra chromosomes are more
sensitive to proteasome inhibitors (46) and cancer cells, which are often aneuploid, also
exhibit increased sensitivity to proteasome inhibitors (52).
One of the most well-known human examples of aneuploidy, is Trisomy 21 in
6

which three copies of the twenty-first chromosome (HSA21) instead of two causes Down
Syndrome (DS) (53). Even though HSA21 is the smallest chromosome in the human
genome, containing only around 300 expressed genes, a single extra copy can lead to
widespread physical, developmental, and intellectual deficits (54, 55). The
supernumerary chromosome causes a 50% average increase in expression of all genes,
but expression is variable on a gene and tissue-specific level with some genes not
overexpressed at all and others overexpressed over 1.5-fold (56). Phenotypic mapping
has been used to determine the genes that underpin specific defects in DS, but one
gene on HSA21 not associated with DS but with other health implications is the Amyloid
Precursor Protein gene, APP (55). APP produces a precursor protein that is then
cleaved into Amyloid-beta: a peptide that forms fibrillar amyloid plaques in the brains of
Alzheimer’s Disease (AD) patients. Interestingly, nearly all brains of deceased DS
patients over 30 years of age featured amyloid plaques similar to those found in AD
patients and DS patients often present with similar neurological defects such as loss of
language skills and ultimately dementia (57, 58). Accumulations of Amyloid-beta plaques
and tau tangles developed two to three decades earlier with three-fold higher rate of
diagnosed dementia in DS patients compared to the non-DS population (57, 58).
Moreover, another neurodegenerative disease associated gene, Cu/Zn superoxide
dismutase (SOD1), is also located on the HSA21. A DS patient with SOD1 mutation
leading to ALS was identified, although overexpression of SOD1 is not generally
considered to be a mechanism of ALS pathogenesis (59).
Many cancers and tumors with increased growth and proliferation phenotypes
feature aneuploidy (60, 61). This correlation is not necessarily causative but can be an
indication of the lack of genomic control (62). Indeed, aneuploidy can be both a cause
7

and an effect of cancer. Several lines of evidence suggest that aneuploidy is not
causative of tumorigensis and is the result of increased rate cell proliferation that can
lead to loss of genomic integrity (46, 63, 64). On the other hand, there are clear
examples where aneuploidy can be oncogenic, which specific genes that are
overexpressed can be transforming (65-69). Studies in yeast have shown that
aneuploidy can be advantageous under some circumstances, where it can alter
transcription profiles to quickly adapt to changing environmental conditions and stress
(70, 71). The instability of the genome in cancer cells may allow them to rapidly explore
aneuploid states for phenotypes that would be most beneficial as host cells attack the
cancer (72, 73). In cancer, aneuploidy is can be context specific, with overexpression of
some genes promoting tumor formation in certain cell types while inhibiting it in others,
but the relative chromosomal instability allows rapid access to variant proteome profiles
that can be potentially advantageous in specific cancer cell niches and can even confer
drug resistance (74). However, the aneuploid nature of many cancer cells might enable
evolutionary traps, which predictably shift the population into a druggable space that
could be readily eliminated (75).
1.2.2 Chromosome Translocations
Chromosome translocations are another alteration in genomic integrity, which is
caused by rearrangement of nonhomologous chromosome that can result in the
misregulation of gene expression (76). Chromosome translocations occur when a
segment of one chromosome is fused to a nonhomologous chromosome or a new site
on the same chromosome (77). Translocations require double-stranded DNA breaks at
two separate chromosomal locations, activation of cellular DNA repair machinery,
followed by anomalous fusion and repair to create novel chromosomes. Depending on
8

the location of the chromosomal lesions and the genes that are affected, disruption and
misregulation of gene function can occur.
One of the first characterized chromosome translocations was in the Philadelphia
chromosome of some chronic myelogenous leukemia (CML) patients, in which the short
arms of chromosomes 9 and 22 are switched (78, 79). This translocation created a novel
fusion protein due to the fusion of the ABL1 gene, originally on chromosome 9, to BCR
on chromosome 22 (80). Further study on BCR-ABL identified the fusion to be an
oncogene in which the kinase activity of ABL was constitutively active, stimulating
proliferation of myeloid cells leading to CML (81). In other cases, translocations do not
result in gene fusions, but instead replace the coding sequence of one gene with another
so that the promoter and enhancer sequences of one gene therefore regulate another.
The first characterized example of this phenomenon was in Burkitt’s lymphoma patients,
in which c-MYC, which regulates the expression of thousands of genes (82, 83), from
chromosome 8 was placed under the control of the highly induced immunoglobulin
heavy-chain gene promoter region on chromosome 14 (84-86). In a contemporary study,
c-MYC was also found to be similarly translocated in mouse plasmacytomas, where it
was also placed under control of an immunoglobulin gene promoter (87-90). The result
of these translocations was loss of regulated, temporal induction of c-MYC replaced with
constitutive, high overexpression, and carcinogensis.
Since the characterization of the oncogenic translocations in the 1980’s, over
60,000 chromosomal aberrations, of which over 10,000 are gene fusions, have been
reported in nearly every cancer type (91). However, chromosome translocation events
associated with lymphomas and leukemia can be found in normal individuals and
present a real cellular challenge that needs to be overcome because the consequences
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for failure to combat these can be dire for the organism (92).
1.2.3. Transcription Factor Activation
Perturbations to transcription factors (TFs) are a common avenue that can lead
to gene misregulation and overexpression. TFs are proteins that control which genes are
expressed by binding to specific, regulatory DNA sequences near the target genes to
stimulate or repress expression (93, 94). Alone or in concert with other proteins, TF
binding to DNA influences the engagement of the RNA polymerase II machinery to the
target DNA, acting either as an activator that recruits RNA polymerase II to transcribe
the gene, or as a repressor that blocks RNA polymerase II binding and thus transcription
(94). TF regulation of the genome is essential. TFs control the repertoire of genes that
are expressed, which is how every cell in our bodies, despite having the same copies of
DNA, can express different genes and have vastly different phenotypes (95, 96). The
most common gene mutated in cancer cells is p53, a TF that acts as a tumor suppressor
when activated by stress, inducing expression of genes that can arrest cell cycle
progression, induce apoptosis, and repair DNA damage (97).
TFs canonically have two separate, modular domains, a DNA-binding domain
(DBD) that binds specific DNA sequences corresponding to enhancer, repressor, or
promoter regions and a trans-activating domain (TAD) that allows for interaction with
other regulatory proteins and the transcription initiation complex (93). TFs may also
contain stimulus-response domains, which upon phosphorylation or binding to ligands
induces a conformational change that activates or deactivates the TF (98, 99). Mutations
to the DBD, TAD, or regulatory regions can lead to changes in the activation of TFs that
can therefore drastically change the composition of the transcriptome (100, 101). The
DBDs of most TFs are relatively short small regions approximately 20-30 amino acids in
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length that bind relatively short DNA sequences that are typically 6-12 bases long (102).
The amino acid composition of the DBD dictates the nucleotide sequences it will bind,
thus mutations to the DBD will affect the strength and stringency of the interaction, the
tolerance for binding modified DNA, and the structural context of the DNA (103, 104).
Single amino acid mutations in the DBD can greatly affect the DNA sequences the TF
can bind to and thus the genes that are expressed. This effect is especially striking
because most TFs are pleiotropic and can influence a large number of genes, one of the
most interesting of which is Pdr1 in yeast (105). PDR1, for “pleiotropic drug resistance,”
was discovered in a survey of yeast strains where mutations in the gene were
discovered to confer resistance to up to 18 different small-molecule drugs with
mitochondrial and non-mitochondrial targets, including the fungicides oligomycin,
Antimycin A, and cycloheximide (106, 107). Characterization of these PDR1 mutations
revealed loss of inhibition and constitutive activation, loss of DNA binding and thus
inactivation, changes in the binding preference for DNA leading to a change in genes
induced, or perturbations in the TAD that leads to differential protein binding and
alterations downstream gene activation (108, 109).
1.2.4. Defects in Protein Degradation
As proteins are being synthesized, they are also constantly turned over,
hydrolyzed by proteases back to amino acids to be reused again (14, 110). The rates of
degradation vary from minutes to months depending on the individual role of each
protein in the cell and are carefully balanced with rate of synthesis (110). Most proteins
are degraded by the ubiquitin-proteasome system (UPS) (111) or by lysosomes via
autophagy (112, 113). In the UPS, ubiquitin is used as a signaling molecule that marks
proteins to be targeted for proteasomal degradation (14, 110). An E1-ubiquitin activating
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enzyme primes the ubiquitin, which is then transferred to an ubiquitin-conjugating
enzyme that along with a E3-ubiquitin ligase covalently attaches the ubiquitin to a lysine
or the N-terminus of a targeted protein (114, 115). Polyubiquitylation can then occur on
lysine 48 of ubiquitin to produce a tag to identify proteins for proteasomal degradation
(14, 110). The proteasome is an elaborate, barrel-shaped protein holoenzyme consisting
of a proteolytic 20S core particle of four stacked heptameric rings that is flanked by a
regulatory 19S particle comprise of base and lid substructures, which unfold and
deubiquitylate substrates prior to entry into the proteolytic chamber for degradation (116,
117). Proteins can also be degraded by delivery to the lysosome by chaperone-mediated
autophagy or macroautophagy. Autophagy is especially crucial for aggregates and
misfolded proteins that may not be degraded by the UPS. Chaperone-mediated
autophagy (CMA) is the selective degradation of protein substrates in the lysosome
(118). In CMA, specific protein substrates are recognized by the heat shock protein,
Hsc70, which targets the substrate to the lysosome surface where the protein is then
translocated into the lysosomal matrix for degradation (119). In macroautophagy, excess
or damaged organelles and entire protein aggregates can be sequestered in double
membrane vesicles called autophagosomes, which then fuse with lysosomes for
degradation and recycling of biosynthetic constituents (120).
Several human diseases feature increased levels of pathogenic proteins due to
deficiencies in the protein degradation pathway including α-synuclein in PD. α-Synuclein
is a small, 140-residue, membrane-associated protein found in the pre-synapse of
neurons (121, 122). While the normal function of the protein is not fully understood
(122), α-synuclein is notable for its formation of beta-sheet rich amyloid fibrils in Lewy
neurites in the processes of synaptic neurons and Lewy bodies in cell bodies of neurons,
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the defining hallmark of PD and other related neurodegenerative diseases termed
synucleinopathies (123-125). Several uncommon mutations as well as gene duplication
have been discovered to lead to heritable cases of PD (36, 121, 126, 127), but in
general most instances are sporadic (128, 129). Characterization of purified α-synuclein
has shown that it is predominantly unfolded and intrinsically disordered in solution (130,
131). These intrinsically disordered regions present an opportunity to form deleterious
interactions that can lead to aggregation (132, 133). In post-mitotic neurons, where
regulation of homeostasis is crucial, several defects were found in the UPS and
autophagy pathways of PD patients, which included reduced proteasome activity and
downregulation of proteasome components in PD patient tissues, and alterations in
proteasome and autophagy function in a rat models of PD (134). Moreover, α-synuclein
has been demonstrated to be targeted for CMA degradation, and CMA defects have
been described in both familial and sporadic PD (135-137). Additionally, studies with
transgenic animals and neurons expressing α-synuclein have found that proteasome
inhibition resulted in accumulation of α-synuclein in dopaminergic neurons and
accelerated neurodegeneration phenotypes (138-140). Furthermore, other studies in PD
patients have found increases in the number of autophagasomes in affected neurons
(141) as well as decreases in the lysosomal markers suggested accumulation of αsynuclein in dysfunctional autophagosomes (142, 143).
c-Myc is another example of a UPS substrate in which a failure in degradation
can lead to inappropriate accumulation and ultimately oncogenesis. c-Myc is a protooncogene that encodes a transiently expressed TF with a normally short half-life of
around 30 minutes in cellsb(144, 145). Phosphorylation at threonine 58 and serine 62
are important for ubiquitylation and degradation by the proteasome (146, 147). However,
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mutations to Thr58 or Ser62 in c-Myc that prevent phosphorylation or in kinases that
phosphorylate these residues can result in a significant decrease in the ubiquitylation
and degradation, leading to accumulation of active c-Myc (148, 149). c-Myc activation of
downstream pathways can lead to rapid cell proliferation and also enhancement of
transformation phenotypes.
1.3 Mechanisms for Dosage Sensitivity Toxicity
The mechanism for toxicity due to gene overexpression and dosage sensitivity
has been the subject of much debate. Initially, Hurst and colleagues proposed the
“balance hypothesis” in which imbalances in the concentration of subcomponents of
protein-protein complexes are deleterious (Fig. 2A) (150). Thus, underexpression or
overexpression of protein complex subunits would confer toxicity. Indeed, several lines
of evidence suggest that the balance hypothesis helps explain reduced fitness due to
underexpression and haploinsufficiency. For example, yeast genes connected with low
heterozygote fitness tend to be in protein complexes (150, 151). The specific topological
arrangements of protein within a complex is an accurate predictor of underexpression
toxicity (152). However, the balance hypothesis has been less able to provide a
compelling explanation of overexpression toxicity of yeast genes where many toxic
proteins are not components of large protein complexes (4, 151). Moreover, in yeast
there is little overlap between genes that are toxic when overexpressed and haploinsufficient genes (42). With the exception of a small set of essential genes, in which the
overexpression phenotype mirrors the deletion phenotype and the overexpressed
protein is known to be a member of multi-subunit complexes, altered protein complex
stoichiometry is not likely the root cause for most instances of overexpression lethality
(4, 42, 151).
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Specific regulatory imbalances appear to be the primary cause of overexpression
toxicity rather than disruption of protein complex stoichiometry (4, 42, 151). At least
~80% of yeast genes are not toxic when overexpressed (4, 42). However, proteins that
are toxic at elevated concentrations due to overexpression tend to have intrinsically
disordered, low-complexity domains (4). Mass-action-driven interaction promiscuity due
to intrinsically disordered, low-complexity domains within proteins has emerged as a
leading theoretical framework to explain why certain protein-coding genes are toxic
when overexpressed (4). In addition, hyperactive gene function (e.g. kinase or
phosphatase activity) is likely important for toxicity of a number of dosage-sensitive
genes (Fig. 2D). The presence of intrinsically disordered, low-complexity domains within
toxic proteins indicates that protein misfolding and potentially aggregation could play a
key role in overexpression toxicity (4, 153). Thus, a novel gain-of-function could arise
due to toxic soluble oligomer formation or aggregate formation (Fig. 2B) (154, 155).
However, intrinsically disordered, low-complexity domains also participate in functional
liquid-liquid phase separation (LLPS) events that underpin the formation of various
membraneless organelles (156-159). Thus, overexpression could lead to inappropriate
or excessive LLPS, which might also be toxic (Fig. 2E) (160). Finally, sequestration of
essential proteins or chaperones, and loss of negative feedback and regulation might
also contribute to overexpression toxicity (Fig. 2F) (42, 43, 161, 162).
Toxic aggregate formation and accumulation is perhaps the easiest to
understand of the mechanisms that cause dosage sensitivity (Fig. 2B). The fact that
dosage-sensitive proteins are generally enriched for unfoldedness, long unfolded
regions, long transcripts, and slow transcription rates suggests that these proteins are
not well folded in their native state and when overexpressed could overwhelm the
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proteostasis network and lead to aberrant aggregate formation that the cell cannot
abrogate (4). Alternatively, these proteins may adopt soluble but toxic oligomeric
conformations like numerous human neurodegenerative disease proteins (163, 164).
Indeed, almost all human neurodegenerative disease proteins contain intrinsically
disordered regions (155, 165, 166). Aberrant oligomerization and aggregation is thought
to be the mechanism for the toxicity of a number of human neurodegenerative diseases,
including ALS, PD, AD, and Creutzfeldt–Jakob disease (167-170).
Another hypothesis for overexpression toxicity is that the toxic protein does not
aggregate but sequesters essential proteins and chaperones via mass-action-driven
interaction promiscuity (4). Dosage-sensitive proteins tend to be enriched in unfolded
regions, which likely increases the burden on the endogenous chaperone machinery. In
essence, overexpressing certain high-burden protein substrates would bind protein
chaperones preventing them from acting on their native substrates, some of which could
be essential, resulting in a net loss of function of certain proteins (Fig. 2F). This type of
dosage sensitivity is not specific to the function of the protein but could potentially be
mimicked by any large influx of highly unfolded protein that demanded the attention of
the protein chaperone system. In addition, misfolded and aggregated proteins with
exposed hydrophobic regions and other residues not usually solvent accessible in the
native conformation could foster aberrant interactions with other soluble proteins, which
can remove these proteins from their proper localization or inhibit their functionality (Fig.
2C).
A probable explanation for the mechanism of dosage sensitivity of certain
proteins is related to the intrinsic activity of the protein itself. The cell is a fine-tuned
machine, which requires all processes to be highly controlled and regulated. For
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example, protein kinases phosphorylate substrate proteins and protein phosphatases
exist to regulate kinase activity by removing phosphates ligated to substrates. Similarly,
fatty acid synthases that create triglycerides to store energy as fat are opposed by
lipases that aid in the digestion of the dietary lipids to allow absorption of catabolized
nutrients. In almost all cases, pairs or groups of proteins exist that oppose the function of
their respective counterparts. However, when the expression of a specific protein is
drastically increased, the cell may not be able to regulate this activity because without
upregulation of its counteracting partner, the overexpressed protein is now
unencumbered in its activity which can lead to defects in growth (Fig. 2D). This
regulatory imbalance can lead to anomalous phosphorylation of proteins, abnormal
activation of genes by TFs, or deleterious depletion of resources, all of which can be
ultimately fatal for the organism.
In this vein, TFs are among the most toxic genes when overexpressed, with more
than double the rate of dosage sensitivity compared to the rest of the genome (42).
Nearly a third of TFs were reported to be dosage sensitive, which makes sense because
TF overexpression can lead to subsequent upregulation of other genes unleashing a
cascade of aberrant gene overexpression. Indeed, TF overexpression often results in
perturbations of known physiological functions and specific expression activation or
repression of their target genes (171). Moreover, TFs often bind to characterized
regulatory DNA sequence motifs proximal to their target genes affecting their expression
patterns (171). TF overexpression leads to the induction of known targets and shows
that overexpression can increase occupancy of TF to their known targets (171). The fact
that overexpression of TFs causes growth defects suggests that their increased activity
may result in pathway activation and dysregulation that results in deleterious
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transcriptome imbalances.
The physicochemical properties and function of a protein seem to dictate whether
it will be toxic upon overexpression. However, the mechanism by which individual
proteins become toxic when overexpressed has typically not been delineated, and as
illustrated above, diverse mechanism may be responsible. This mechanistic diversity
complicates the development of agents that counter toxicity of diverse dosage-sensitive
genes. Indeed, is it even possible to define a single, wide-reaching solution for genes
that are harmful and can cause disease when overexpressed? The answer seemed to
be “no” because the mechanisms by which genes might be deleterious when
overexpressed are numerous and diverse. However, because Hsp104 is able to unfold
many proteins that can be damaged during cellular stress, it seemed to be a promising
candidate to pursue.
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Figure 2: Possible mechanisms of dosage sensitivity.
A. Overexpression of one component of a multi-protein complex can lead to loss of
stoichiometric balance and formation of nonfunctional intermediates. The phenotype
overexpression phenotype for these types of proteins may be the same as gene
deletion. B. Overexpression of intrinsically disordered or aggregation-prone proteins
could lead to the formation of toxic soluble oligomers or large aggregates. C.
Overexpression of toxic aggregation-prone proteins could lead to aggregates that form
non-native interactions with soluble protein and remove them from the cytosol. D.
Overexpression of a kinase (e.g. kinase in blue) could lead to overactive kinase activity
leading to excessive phosphorylation (yellow star) of a substrate (light green) resulting in
increased downstream signaling. Without commensurate upregulation of the
endogenous phosphatase (dark green), hyperphosphorylation is left unchecked. E.
Overexpression of proteins with intrinsically unfolded, low-complexity regions can lead to
generation of liquid-liquid phase separations (LLPS) events which may be toxic. F.
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Overexpression of difficult-to-fold substrates could lead to sequestration of chaperones
and subsequent misfolding of other proteins, some of which could be essential for
viability.

1.4 Hsp104 is a Potent Protein-Remodeling Factor and Protein Disaggregase
In the brewer’s yeast Saccharomyces cerevisiae, Hsp104 is a hexameric, ringshaped AAA+ (ATPases associated with diverse cellular activities) protein and a potent
protein-remodeling factor and protein disaggregase of the Hsp100 family (172, 173). It is
an essential protein for yeast to tolerate diverse stresses and is greatly induced following
low and high temperature shock and chemical stresses (173). Unlike most protein
chaperones like Hsp40, Hsp70, and Hsp90 that facilitate folding of nascent polypeptides,
the primary function of Hsp104 is to disaggregate and refold stress-induced, aggregated
and misfolded proteins, returning these proteins back to their native form (32, 174, 175).
Its aggregated substrates in yeast can include a diverse set of structures from
amorphous aggregates formed during heat shock to highly-ordered, fibrillar amyloids of
a single species like the Sup35, Rnq1, and Ure2 prions that underpin the non-Mendelian
elements [PSI+], [RNQ+], and [URE3+], respectively (176-179). However, Hsp104
activity is not restricted to just aggregated substrates. Hsp104 is also a powerful proteinremodeling factor capable of disassembling soluble toxic oligomers formed by diverse
proteins (177, 180-182). Hsp104 can also convert intrinsically disordered prion domains
into self-replicating prion conformers under certain conditions (177, 180). Finally,
Hsp104 can act as an unfoldase, which under some circumstances (e.g. in vitro in the
presence of ATP and ATPγS) unfold natively-folded proteins like GFP provided they are
appended to an intrinsically disordered domain (183).
Hsp104 is a member of the Hsp100 family of molecular chaperones, which
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contain highly conserved AAA+ domains that utilize the energy from ATP hydrolysis to
remodel protein substrates (184, 185). Hsp104 contains two AAA+, nucleotide-binding
domains (NBD1 and NBD2), a middle domain (MD) separating the two NBDs, and an Nterminal domain (NTD) and C-terminal domain (CTD) flanking the NBD1 and NBD2
respectively (Fig. 3A). Hsp104 forms barrel-shaped hexamer in vivo, in which the NTD,
and the two NBDs form a set of three stacked rings surrounding a hollow central pore
through which substrate is translocated (Fig. 4) (186, 187). Recent studies show that the
Hsp104 can adopt an asymmetric helical architecture with the AAA+ domains forming a
two-turn spiral around the central pore axis (Fig. 3B) (188). The NTD is involved in
substrate specification and engagement, and enables optimal disaggregase activity
(189). Once engaged, the protein substrate is subsequently bound to conserved
substrate-binding tyrosines on pore loops inside the channel in each of the NBDs (190,
191). Hsp104 utilizes ATP hydrolysis to translocate the protein through the central pore
thus unfolding it (Fig. 4) (174, 190, 191). The MD can regulate Hsp104 activity by
forming autoinhibitory interactions with NBD1 to repress the activity of the protein and by
establish inter-protomer bridges across the nucleotide-binding pocket to control ATP
hydrolysis and thus Hsp104 function (188, 192, 193). The role of the CTD is not as well
understood, but it is require for the hexamerization of Hsp104 (194).
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Figure 3: Domain architecture and structure of Hsp104.
A. Domain architecture of Hsp104 with corresponding residues. B. Multiple views from a
3D density map of Hsp104 obtain by Cryo-EM. The domains, shaded the same colors as
in part A, are arranged in a left-handed, three-tiered spiral with an asymmetric seam
between the first and sixth protomer of the hexamer. Axial and longitudinal dimensions
of the whole protein (black) and the central pore (grey) are given. (Adapted with
permission from Nature Publishing Group, License Number: 3944951097151) (188).
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Figure 4: Model of Hsp104 disaggregation of diverse substrates.
Hsp104 in collaboration with Hsp40s and Hsp70s, binds a wide variety of substrates
including amorphous aggregates and highly-ordered aggregates through interactions in
the N-terminal domain (NTD). The protein substrates are translocated through the
central pore of Hsp104 where substrate-binding tyrosines on pore loops in the two
nucleotide-binding domains (NBD1, NDB2) powered by ATP hydrolysis provide the
locomotive force to unfold and thread the substrate through the hexamer to solution.

In yeast, Hsp104 is crucial for the disaggregation and maintenance of proteins
that are associated with aging. Deletion of Hsp104 resulted in an accelerated aging
phenotype and reduction in longevity (195). As organisms age, protein homeostasis
integrity declines in all aspects from diminished chaperone activity, increased amounts
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of misfolded and aggregated protein, and decreased proficiency of protein degradation
systems (15, 196-199). This deficiency in maintaining proteostasis combined with
increasing amounts of oxidative stress (200, 201) can result in the accumulation of toxic
protein that further exacerbates the aging phenotype (202, 203). Yet, despite its
seemingly indispensible function in preserving proteostasis and limiting the effects of
aging, Hsp104 homologs are not conserved in the metazoan lineage of evolution.
Indeed, although conserved in eubacteria, some archaebacteria, and the vast majority of
eukaryotes including all fungi, plants, protozoa, and algae, Hsp104 is conspicuously
absent in animals (204, 205). Although some Hsp104 functions are preserved in other
molecular chaperones complexes, notably the Hsp110, Hsp70, and Hsp40 system (35),
the loss of Hsp104 is highly puzzling considering the myriad benefits it bestows upon the
host. Considering the greatest risk factors for human neurodegenerative disease is
aging (206), this lack of Hsp104 presented an opportunity for designing and introducing
bespoke Hsp104 variants that can target aggregation-prone proteins, especially those
implicated in several incurable human neurodegenerative disease (207-210).

1.5 Engineering Potentiated Hsp104 Variants
Encouragingly, Hsp104 is well tolerated in metazoan systems and can
collaborate with mammalian Hsp110, Hsp70, and Hsp40 molecular chaperones to
remodel aggregated protein (35). Furthermore, wild-type Hsp104 has the ability to
remodel the protein aggregates and mitigate the symptoms associated with ALS (211),
PD (182), AD (212), and HD (213-216) in animal models of human neurodegenerative
disease. Moreover, Hsp104 can disaggregate a diverse panel of amyloid fibrils formed
by neurodegenerative disease proteins (181). However, this ability to cure
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neurodegenerative disease phenotypes is limited and in some cases, Hsp104 may
actually enhance toxicity of some disease-associated proteins (217). To improve on the
native function of Hsp104, genetic variants of Hsp104 were systematically generated
and screened in yeast for the ability to suppress toxicity of TDP-43 and FUS, each
implicated in ALS and Frontotemporal Lobar Degeneration (FTLD), and also αsynuclein, which has an active role in the development of PD (207-210). Compared to
Hsp104, which had limited efficacy in suppressing disease protein toxicity, many of the
mutants generated were far more effective (207-209).
An uncovered Hsp104 variant that was one the best suppressors of α-synuclein,
TDP-43, and FUS toxicity in yeast contained an A503V mutation (Hsp104A503V) (207210). The A503 is in helix 3 of the coiled-coil, middle domain of Hsp104, which is
important for ATPase activity, coordination of NBD1 and NBD2 activity, disaggregation,
and forming interactions with Hsp70 that can promote protein disaggregation (192).
Given its crucial role in regulating so many processes and interaction, it is perhaps not
surprising that previous studies of MD variants found that mutations in this region could
be toxic to the organism or also have beneficial gain-of-function phenotypes (218).
Mutational characterization found that nearly all mutations at the 503 position enhanced
Hsp104 suppression of toxicity to varying degrees and only A503P had no effect or
increased toxicity of the toxic disease-associated proteins (207). Hsp104A503V was able
to suppress toxicity and aggregation of α-synuclein, FUS, and TDP-43 in yeast restoring
solubility and proper localization, without drastically decreasing toxic protein expression
and independent of the unfolded protein response and autophagy pathways (207).
Hsp104A503V and Hsp104A503S could also disaggregate preformed α-synuclein, FUS, and
TDP-43 fibrils in vitro at concentrations where Hsp104 was inactive (207). Hsp104A503S,
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which has very similar activity to Hsp104A503V, was tested in a C. elegans model of PD
(207). In this PD nematode model, human α-synuclein is overexpressed in the
dopaminergic neurons, resulting in severe neurodegeneration, which worsens as the
animals age (219). Hsp104A503S co-expression in the dopaminergic neurons was
protective, significantly increasing the number of worms with the complete complement
of dopaminergic neurons (207). Biochemical studies of in vitro purified Hsp104A503V
demonstrated that compared to Hsp104, Hsp104A503V exhibited elevated ATPase rate,
superior disaggregation function even without Hsp70 and Hsp40, improved substrate
translocation efficiency, and the enhanced ability to unfold soluble protein (207).
The significant efficacy of Hsp104A503S in mitigating the toxicity of several dosagesensitive human neurodegenerative disease proteins in yeast and α-synuclein in a
nematode model of PD led us to interrogate the extent of the buffering capacity of
Hsp104A503S. Thus, we tested Hsp104A503S against a battery of dosage-sensitive yeast
proteins to obtain a more global picture of the repertoire of toxic proteins Hsp104A503S
can rescue.
1.6. Overarching Goal of Thesis.
The overarching goal of this thesis was to rationally engineer a ‘buffer’ that
universally mitigates the toxicity of dosage-sensitive genes, i.e. genes that are toxic
when overexpressed. By introducing the A503S mutation into Hsp104, we have
engineered an enhanced protein-remodeling factor that antagonizes the toxicity of a
remarkable number of dosage-sensitive genes. The results of my studies are presented
in the next chapter.
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CHAPTER 2: SUPPRESSING DOSAGE LETHALITY WITH HSP104A503S
2.1 Introduction
Hsp104A503S was very effective at suppressing the toxic aggregation phenotypes
in our yeast neurodegenerative disease models in which disease-associated proteins
(e.g. TDP-43, FUS, or α−synuclein) are overexpressed (207-210). Thus, we investigated
the ability of Hsp104A503S to combat dosage sensitivity caused by overexpression of
endogenous yeast proteins. We hypothesized that if overexpression of some proteins
causes proteostatic stress due to the formation of soluble toxic oligomers, toxic
aggregates, or inappropriate liquid-liquid demixing phase transitions, then Hsp104A503S
should be able to disassemble these toxic species and suppress the deleterious effect of
dosage sensitivity. Dosage-sensitive screens have been used to determine substrates of
proteins such as kinases, phosphatase, transcription factors, and other proteins (42,
220), as well as dissect complex pathways such as kinetochore assembly, chromosome
segregation, establishing cell polarity, histone regulation of transcription, and cell cycle
progression (221-224). We overexpressed genes that caused a growth defect in yeast,
to identify genes whose toxicity was suppressed by Hsp104A503S. We predicted these
genes would code for protein substrates that Hsp104 could directly bind, disaggregate or
remodel, and detoxify. We expected Hsp104 to have a limited capacity to suppress
dosage-sensitive proteins because of its restricted ability to combat the most toxic
human disease-associated proteins in our yeast models, but Hsp104A503S would be able
to suppress a greater number of dosage-sensitive genes because in the same context it
has proven to be more effective (207-210). Because dosage-sensitive proteins and
many aggregation-prone disease proteins commonly have large portions that are
unfolded and disordered (4), we further postulated that Hsp104A503S would engage these
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toxic proteins through their exposed, unstructured low-complexity domains, and unfold
the complete toxic protein via ATPase-coupled translocation across the central Hsp104
channel. This coupled unfoldase and translocase activity would also unfold monomeric
soluble protein, disassemble soluble toxic oligomers, disaggregate aggregated
structures, and denature toxic conformers. Moreover, the increased ATPase activity of
Hsp104A503S enables it to complete its reaction cycle more rapidly (207). Thus, we
expected Hsp104A503S to be a significantly more robust inhibitor of dosage sensitivity
because it would be able to remodel more toxic substrates than Hsp104 per unit time. In
essence, we suspected that the hyperactive protein-remodeling activity of Hsp104A503S
would be extremely beneficial when cells are challenged with the overexpression of a
single toxic protein.
2.2 Results
2.2.1 Hsp104A503S but Not Hsp104 Suppressed Most Instances of Dosage
Sensitivity
We previously screened the FLEXGene overexpression plasmid library (225) for
candidate genes that were toxic when overexpressed in the BY4741 yeast strain in both
the wild-type background and with HSP104 deleted. We did not find a substantial
number of genes with significant difference in toxicity when expressed in the wild-type
background compared to Δhsp104. From those hits we created a small library of 198
plasmids containing genes marked as potentially dosage-sensitive (Table 1). Each gene
was individually arrayed onto a 96-well tissue culture plate to be used in high-throughput
yeast transformations. In this study, each plasmid was individually transformed into
Δhsp104 yeast to create strains containing an empty pAG413Gal vector (BYV),
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pAG413Gal-Hsp104 (BYW), or pAG413Gal-Hsp104A503S (BYA) to determine if either
Hsp104 or Hsp104A503S overexpression could suppress the toxicity of each induced
dosage-sensitive gene (Fig. 5A). The pAG413Gal plasmid system was chosen for
expressing Hsp104 because the centromeric element ensures a relatively consistent,
low copy number per cell (1-2), the Gal1-10 promoter produces robust inducible
expression with galactose-containing media (and strong repression on glucose to enable
routine passage of yeast), and the HIS3 gene allowed for positive selection of the
plasmid in BY4741 yeast. The toxicity of each dosage-sensitive gene in the BYV, BYW,
and BYA yeast strains was scored on a scale of 0 to 5, with 0 corresponding to no
toxicity and 5 corresponding to full toxicity and no growth (Fig. 5B). Confirming previous
results (207), Hsp104A503S strongly suppressed the toxicity of α-synuclein, FUS, and
TDP-43 (Fig. 5C).
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KIN2
TRM11

YDR216W
YDR251W

ADR1
PAM1

YNL074C

MLF3

YOR156C

NFI1

YDR395W

SXM1

YGR140W

CBF2

YMR257C

PET111

YGL216W

KIP3

YPL202C

AFT2

YIL119C

RPI1

YOL104C
YMR258C

NDJ1
YMR258C

YER125W
YLR347C

RSP5
KAP95

YIL031W
YDR159W

ULP2
SAC3

YBL097W
YPL212C

BRN1
PUS1

YGL003C

CDH1

YGL016W

KAP122

YKL166C

TPK3

YOL112W

MSB4

YPL269W

KAR9

YPR181C

SEC23

YLR341W

SPO77

YNL108C

YNL108C

YGR109C
YBL054W

CLB6
YBL054W

YMR179W
YNL224C

SPT21
SQS1

YJL042W
YER129W

MHP1
SAK1

YKR004C
YBL103C

ECM9
RTG3

YBL029W

YBL029W

YAL031C

GIP4

YBL107C

YBL107C

YNL076W

MKS1

YBR182C

SMP1

YDR306C

YDR306C

YGL049C

TIF4632

YJL013C

MAD3

YPL270W
YDL088C

MDL2
ASM4

YOR113W
YBR273C

AZF1
UBX7

YMR219W
YPL137C

ESC1
GIP3

YER133W
YBR049C

GLC7
REB1

YJL069C

UTP18

YOL006C

TOP1

YCL048W

SPS22

YCR091W

KIN82

YGL224C

SDT1

YCL056C

YCL056C

YPL190C

NAB3

YGL190C

CDC55

YDL155W
YNL047C

CLB3
SLM2

YPL248C
YER169W

GAL4
RPH1

YNL020C
YML068W

ARK1
ITT1

YNR031C
YER047C

SSK2
SAP1

YPL255W

BBP1

YER167W

BCK2

YHR172W

SPC97

YBL063W

KIP1

YNL311C

SKP2

YDR293C

SSD1

YFR023W

PES4

YLL003W

SFI1

YPL153C
YLR057W

RAD53
YLR057W

YPR120C
YML016C

CLB5
PPZ1

YHR086W
YOL027C

NAM8
MDM38

YML010W
YDR103W

SPT5
STE5

YNL188W

KAR1

YML081W

YML081W

YPR065W

ROX1

YOL089C

HAL9

YGL162W

SUT1

YDR430C

CYM1

YBL009W

ALK2

YPR119W

CLB2

YDL224C
YLR241W

WHI4
YLR241W

YKR021W
YDR393W

ALY1
SHE9

YHR177W
YAL025C

YHR177W
MAK16

YGR249W
YNR034W

MGA1
SOL1

YMR153W

NUP53

YHR082C

KSP1

YIL105C

SLM1

YKL068W

NUP100

YOR329C

SCD5

YML034W

SRC1

YDR505C

PSP1

YNL091W

NST1

YMR032W
YEL009C

HOF1
GCN4

YDR212W
YDR096W

TCP1
GIS1

YLR026C
YKL089W

SED5
MIF2

YPL070W
YPR147C

MUK1
YPR147C

YPL115C

BEM3

YHR070W

TRM5

YBR179C

FZO1

YMR111C

YMR111C

YBR250W

SPO23

YJR132W

NMD5

YBR059C

AKL1

YBR289W

SNF5

YOL105C
YKR052C

WSC3
MRS4

YOL013C
YJL092W

HRD1
HPR5

YKR096W
YBR156C

YKR096W
SLI15

YFL037W
YDR335W

TUB2
MSN5

YBL031W

SHE1

YML031W

NDC1

YPL237W

SUI3

YGL150C

INO80

YCL029C

BIK1

YOR212W

STE4

YPR104C

FHL1

YDL233W

YDL233W

YPL184C
YGL122C

MRN1
NAB2

YMR182C
YBR083W

RGM1
TEC1

YFL016C
YAR042W

MDJ1
SWH1

YER164W
YGL073W

CHD1
HSF1

YGR083C

GCD2

YHR098C

SFB3

YDR356W

SPC110

YDL195W

SEC31

YLR253W

YLR253W

YIL006W

YIA6

YHR084W

STE12

YBR158W

AMN1

YLR332W

MID2

YNL183C

NPR1

Table 1: Dosage-sensitive genes screened for Hsp104A503S suppression.
These 198 genes were selected after a previous genome-wide screen in BY4741 for
potential dosage sensitivity. Systematic and standard names are given for each gene.
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Figure 5: Protocol for screening and scoring dosage-sensitive genes.
A. An overexpression plasmid library of potentially dosage-sensitive genes was
screened to determine which toxic yeast genes could be suppressed by Hsp104 or
Hsp104A503Sexpression. The transfected yeast were serially diluted and plated on
Glucose (control) and Galactose-containing (overexpression) plates. Toxic genes that
were strongly suppressed (yellow star) by Hsp104A503S, weakly suppressed (red star), or
not suppressed at all (blue star) were identified. B. Genes were scored on a toxicity
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scale from 0 to 5, with 5 corresponding to the greatest toxicity (BIK1) and 0 for genes
with no toxicity (UTP18). C. Human neurodegenerative disease proteins, TDP-43, FUS,
and α-synuclein were expressed with an empty vector, Hsp104, and Hsp104A503S
coexpression (n = 4 independent transformations).

Surprisingly, Hsp104A503S suppressed the toxicity of the overwhelming majority of
dosage-sensitive genes (97.5%), whereas Hsp104 overexpression was almost
completely ineffective (Fig. 6). In the heat map, red is used to represent toxicity of the
overexpressed gene and blue is the suppression of toxicity (“Rescue”) of each gene by
Hsp104A503S, which is the difference in toxicity from the BYA strain compared to BYV.
Only genes with an average toxicity score of 0.75 or greater are shown on this heatmap
(120 of 198 screened) and they are sorted by “Rescue” (with the greatest Hsp104A503S
suppression of toxicity listed first to those with Hsp104A503S enhancement of toxicity listed
last). There were only three genes of the 120 toxic genes (2.5%) that were not rescued
by Hsp104A503S (Fig. 6). KAR1 toxicity was not suppressed by Hsp104A503S, whereas
MUK1 and TRM5 toxicity was slightly enhanced by Hsp104A503S (Fig. 6). By contrast, the
vast majority of toxic genes (117 of 120 or 97.5%) are suppressed by Hsp104A503S (Fig.
6). Indeed, 95% (114 of 120) of cases of dosage sensitivity were rescued by Hsp104A503S
by a score of 0.5 or more and 72.5% (87 of 120) were rescued by a score of 1.0 or more
(Fig. 6). The difference in toxicity is just as stark on the spotting assay plates from which
the quantification was obtained. The expression of the 30 most suppressed toxic genes,
such as AKL1 and SFI1, results in virtually no growth in BYV or BYW but featured nearly
full growth in BYA (Fig. 7). Even in examples where toxicity is more moderate like the
top half of the second column of spottings in Fig. 7, the suppression of toxicity by
Hsp104A503S is glaring and unmistakably obvious. To the best of our knowledge,
Hsp104A503S is the first agent discovered to rescue such a large proportion of dosage32

sensitive yeast genes.

Figure 6: Hsp104A503S suppresses the toxicity of most dosage-sensitive yeast
genes.
Heat map depicting the toxicity of each dosage-sensitive gene in each strain ranked by
Hsp104A503S suppression of toxicity from greatest to least. Human neurodegenerative
disease gene toxicity is shown at the end of the chart. Red indicates increased toxicity,
blue indicates increased rescue by Hsp104A503S, yellow indicates increased toxicity
enhancement (n = 3-5 independent transformations)
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Figure 7: Hsp104A503S but not Hsp104 suppresses the toxicity of most dosagesensitive yeast genes.
Representative spotting assays from all toxic genes, sorted by suppression of toxicity by
Hsp104A503S from most to least rescue. Heat maps from Fig. 1C were aligned to the
corresponding spotting.

To further emphasize the difference between Hsp104 and Hsp104A503S
suppression of overexpression toxicity, the toxicity score of each gene in the BYW and
BYA strains were compared to the control BYV in a scatter plot. The toxicity score of
each gene in the vector control strain was plotted on the x-axis with the toxicity score of
the gene in BYW (Fig. 8A) or BYA (Fig. 8B) on the y-axis. The best-fit linear regression
of the data for the BYW-BYV comparison has a slope of 0.9290 ± 0.0243, with a
coefficient of determination (r2) value of 0.9251 (Fig. 8A). This very strong positive
correlation (where the slope and r2 values are each very close to 1) indicates that
Hsp104 had an almost no effect on suppressing dosage sensitivity (Fig. 8A). Only a few
genes, TPK2, SHE1, KIP3, GIP4, and HSF1, showed a difference in toxicity score of one
or more between the BYV and BYW strains (Fig. 8A). Hsp104 weakly rescued the
toxicity of HSF1, but enhanced toxicity of TPK2, SHE1, KIP3, and GIP4 (Fig. 6, 7, 8A). In
sharp contrast, Hsp104A503S suppressed the toxicity of almost all toxic genes, which is
immediately evident in the scatter plot, with most data points featuring a y-coordinate
value (Fig. 8B). The best-fit linear regression of the data for the BYA-BYV had a slope of
0.1980 ± 0.0393 and r2 value of 0.1769 (Fig. 8B). The flat slope of the linear regression
fit and very low r2 value indicates that gene toxicity in BYV did not correlate with gene
toxicity in BYA and that overall despite increasing toxicity of some genes in the BYV
strains, Hsp104A503S overexpression was able to suppress toxicity greatly (Fig. 8B). The
vast majority of toxic genes were suppressed in BYA (Fig. 6, 7, 8B). Only KAR1, ITT1,
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MKS1, and GAT3 exhibited toxicity greater than 2 in BYA (Fig. 6, 7, 8B). For these
genes, only KAR1 toxicity was unaffected by Hsp104A503S, whereas Hsp104A503S slightly
reduced ITT1 toxicity and moderately reduced toxicty of MKS1 and GAT3 (Fig. 6, 7, 8B).
MUK1 and TRM5 were the only two genes in which toxicity was slighly enhanced by
Hsp104A503S (Fig. 6, 7, 8B). We also tested the ability of another potentiated Hsp104
variant, Hsp104A503V (207), to rescue all dosage-sensitive yeast genes. Remarkably, the
results were very a similar to Hsp104A503S, and Hsp104A503V suppressed toxicity of nearly
all dosage-sensitive yeast genes (data not shown). Thus, Hsp104A503X mutants (except
Hsp104A503P) might all be hyperactivated in a very similar manner and be broadspectrum inhibitors of overexpression toxicity in yeast.
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Figure 8. Overexpression of Hsp104A503S but not Hsp104, Ssa1, or Hsp82
suppresses dosage sensitivity.
Scatter plot of toxicity of dosage-sensitive genes in yeast expressing Hsp104 (A),
Hsp104A503S (B), Ssa1 (C), and Hsp82 (D) on the y-axis compared the vector control on
the x-axis. The best-fit linear regression line is plotted in black.
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2.2.2 Ssa1 and Hsp82 Overexpression Do Not Suppress Dosage Sensitivity
To determine the specificity of Hsp104A503S dosage suppression, we also
generated Δhsp104 yeast strains overexpressing either SSA1 (BYS) or HSP82 (BYH)
(Fig. 9A, B). Ssa1 is a yeast Hsp70-family chaperone that is crucial for assisting folding
of newly translated protein, preventing misfolding, shuttling aberrantly folded proteins for
degradation, and ensuring proper protein transport to its final destination (226, 227). In
addition, Ssa1 also collaborates with Hsp104 to disassemble protein aggregates and
regulate yeast prions (32, 33, 228, 229). In the absence of Hsp104, Ssa1 combines with
Sse1 (Hsp110) and Sis1 (Hsp40) to disaggregate various aggregated structures (35,
230). Despite high cytosolic concentrations of Ssa1 and other Hsp70-class proteins in
yeast, Ssa1 expression is greatly induced following heat or environmental stress
suggesting that it is crucially needed under crisis conditions (231, 232). Yet, despite the
importance of Ssa1 in maintaining proteostasis, we found that Ssa1, much like Hsp104,
did not suppress the toxicity of most dosage-sensitive genes (Fig. 8C). There were a few
exceptions. For example, Ssa1 potently suppressed toxicity of SQS1, REB1, YDR306C,
ESL2, and HSF1 more than Hsp104 and slightly enhanced TDA9 toxicity (Fig. 8C). In
general, most cases of overexpression toxicity were unaffected by Ssa1 overexpression
where the best-fit linear regression for the BYS-BYV data has a slope of 0.9588 ±
0.0290, with a coefficient of determination (r2) value of 0.9034 (Fig. 8C).
We also tested Hsp82 for its ability to suppress dosage sensitivity. Hsp82 was an
appealing candidate to test as a potential regulator of dosage sensitivity because it is an
Hsp90-class chaperone that assists in the folding of metastable substrates that have
difficulty achieving their final stable conformations (233). Typically, Hsp90-chaperones
assist in protein maturation, acting only on proteins that have nearly reached their final
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form (234). It also has a vital responsibility in folding aggregation-prone substrates and
refolding stress or chemically-denatured proteins back to their native state (233, 235).
Moreover, Hsp82 is critical for the correct folding of many regulatory and signaling
proteins like kinases and TFs, many of which are dosage-sensitive (236-238). We
expected Hsp82 to aid in the folding of some substrates to the native, active form
potentially increasing the toxicity of some proteins while preventing misfolding of other
proteins and suppressing their toxicity. However, when Hsp82 was overexpressed with
the genes in the dosage-sensitive library, it did not affect the dosage sensitivity of many
genes (Fig. 8D). Compared to the vector control, Hsp82 slightly enhanced the toxicity of
RPH1, PDS1, GIP4, SWH1, AZF1, and SLK19 while subtly suppressing the toxicity of
NUP100, SKN7, and ESL2 (Fig. 8D). Overall, however, the best-fit linear regression of
the data for the BYH-BYV comparison has a slope of 0.9766 ± 0.0260, with a coefficient
of determination (r2) value of 0.9260, which demonstrates almost no meaningful
difference between toxicity of genes in the vector control compared to yeast
overexpressing Hsp82 (Fig. 8A).
These results support that Hsp104A503S has a unique activity in broad-scale
suppression of dosage sensitivity that is not easily replicated by overexpression of other
chaperones. Thus, neither Hsp104, Ssa1, nor Hsp82 rescued more than a handful of
dosage-sensitive yeast genes. By engineering Hsp104 to enhance protein-remodeling
activity via introduction of the A503S mutation in the middle domain, we have generated
a powerful buffer able to counter the toxicity of diverse and numerous dosage-sensitive
genes.
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Figure 9. Ssa1 and Hsp82 are induced in yeast.
Ssa1 (A) and Hsp82 (B) were significantly induced following transformation of a plasmid
carrying pAG413Gal-Ssa1 and pAG413Gal-Hsp82 in BY4741Δhsp104. Part B, shows 3
independent transformations and inductions.

2.2.3 Characteristics of Dosage-sensitive Genes
The dosage-sensitive genes that were suppressed by Hsp104A503S shared many
features with previously described dosage-sensitive genes and fell into several general
functional categories that are commonly enriched in dosage-sensitive genes (239): TFs,
cytoskeleton, cell cycle/mitosis regulators, kinases, or phosphatases (Fig. 10A). GO
(gene ontology) Term analysis for “Function” terms were primarily enriched for TFassociated terms related to DNA binding or interactions with RNA Polymerase II
complex (Fig. 10B). GO Term analysis for “Component” terms returned mostly
cytoskeletal and cell cycle-related terms (Fig. 10B). Bioinformatic analysis of the dosagesensitive genes revealed that 7 of 10 most enriched terms were for protein unfoldedness
(Fig. 11A), consistent with other studies of dosage-lethality (4). Dosage-sensitive
proteins are also highly enriched in linear sequence motifs (4). These linear motifs are
short protein sequences that can be recognized by common signaling domains,
phosphorylated by Serine/Threonine- or Tyrosine-kinases or mediate binding
interactions with protein or phospholipids (240). The enrichment of linear sequence
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motifs in dosage-sensitive proteins provides support for the interaction promiscuity
hypothesis for dosage sensitivity, which posits that these exposed linear motifs may
provide additional modalities for aberrant interactions (4).
47 of the 120 dosage-sensitive yeast genes were determined to have human
homologs by sequence homology (Table 2). Of these, 10 yeast genes, HRD1, FKH1,
FHL1, HSF1, KIP1, KIP3, PBS2, SMP1, TUB2, and RSP5, have human homologs with
OMIM (Online Mendelian Inheritance in Man) annotated disease associations, which are
varied including renal cell carcinoma, mental retardation, and anemia (Table 2).
Of the 120 toxic genes, the localization of 91 proteins was reported in a global
analysis of localization in yeast where each gene was C-terminally GFP tagged in its
original chromosomal location (241). The localization profile of the dosage-sensitive
proteins was similar to those of all proteins in general (Fig. 11B), with about half of the
toxic proteins (45 of 91, 49.5%) reported as localized to the cytoplasm compared to
studies that estimated 47% all proteins to be cytoplasmic in proteome-wide studies
(242). However, there are some differences from reported subcellular
compartmentalization of yeast proteins. The biggest outlier is the enrichment of nuclear
proteins in the dosage-sensitive set, 43 of 91 (47.3%) annotated genes (Fig. 11B), which
is greater than the 27% reported for the entire yeast proteome (242). In large part, this is
due to overrepresentation of transcription factors in the dosage-sensitive gene library,
with accounted for nearly 20% (21 of 120) of toxic genes in the library we created (Fig.
10A). In contrast, genes in the mitochrondia and exocytic networks (ER, Golgi, and
secretory pathways), reported to be approximately 13% of the proteome each
respectively (242), were underrepresented in our dosage-sensitive gene set (Fig.11B).
The large proportion of genes that are localized to the cytoplasm, nucleus, or both and
42

relatively few number of genes localized to membrane isolated organelles allows
Hsp104A503S to easily engage these substrates.

43

Figure 10. Features of dosage-sensitive genes suppressed by Hsp104A503S.
A. Toxic genes with toxicity as shown in Fig. 1C grouped by function. B. The Gene
Ontology Term Finder reveals significant enrichment of genes with DNAbinding/Transcription Factor associated “Function” terms and cytoskeletal or nuclear
“Component” terms.
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Figure 11. Dosage-sensitive proteins are enriched for predicted disorder or
unfoldedness and generally localized to the nucleus or cytoplasm.
A. Dosage-sensitive gene set was compared to the rest of the genome for features that
were correlated with dosage sensitivity. A cross-validation experiment was used to
determine the predictiveness of each feature for gene dosage sensitivity. The mean area
under a receiver operating characteristic (ROC) curve for each of the cross-validation
experiments was plotted for each feature. 7 of the top 10 most correlated terms are
associated with predicted intrinsic protein disorder (IUcount, ANCHORcount, FInumaa,
Intrinsic.Disorder.GlobPlot, IUmaxrun, Intrinsic.Disorder, DisEMBL.COILS, FImaxrun),
the others refer to protein length, enrichment for linear motifs (ELMcount), and high
Asparagine content. Analysis performed by Oliver King. B. Each dosage-sensitive gene
with a reported localization (91 of 120) from a global study was counted and the
distribution by localization terms are given (241). The localization categories are not
mutually exclusive with over 30 assigned two or more localization including 16 that were
reported as having both cytoplasmic and nuclear localization.
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Yeast
Gene

Yeast
Systematic

Human Homolog

Human Diseases Associated
with Gene

ARK1

YNL020C

AAK1, BMP2K

AKL1

YBR059C

AAK1, BMP2K

RNH70

YGR276C

AC004381.6, REXO1,
REXO1L11P, REXO1L1P,
REXO1L10P

HRD1

YOL013C

AMFR, SYVN1, RNF145, RNF139

NAM8

YHR086W

C6orf52, TRNAU1AP

CLB6

YGR109C

CCNB1, CCNB2, CCNE2, CCNE1,
CCNB3

CLB3

YDL155W

CCNB1, CCNB2, CCNE2, CCNE1,
CCNB3

CLB2

YPR119W

CCNB1, CCNB2, CCNE2, CCNE1,
CCNB3

CLB5

YPR120C

CCNB1, CCNB2, CCNE2, CCNE1,
CCNB3

CDH1

YGL003C

CDC20B, CDC20, FZR1

CHD1

YER164W

CHD5, CHD4, CHD3, CHD1, CHD2

SUI3

YPL237W

EIF2S2

FKH1

YIL131C

FOXJ1, FOXK1, FOXK2

Allergic Rhinitis (FOXJ1)

FHL1

YPR104C

FOXN1, FOXN4, FOXH1

Immunodeficiency, Congenital
Alopecia, and Nail Dystrphy (FOXN1)

HSF1

YGL073W

HSF1, HSF2, HSF4

Cataracts (HSF4)

INM1

YHR046C

IMPA1, IMPA2

SXM1

YDR395W

IPO7, IPO8

NMD5

YJR132W

IPO7, IPO8

RPH1

YER169W

KDM4B, KDM4C, KDM4D, KDM4E,
KDM4A

GIS1

YDR096W

KDM4B, KDM4C, KDM4D, KDM4E,
KDM4A

KIP1

YBL063W

KIF11

Microcephaly

KIP3

YGL216W

KIF19, KIF18B, KIF18A, KIF22

Spondyloepimetaphyseal Dysplasia
with Joint Laxity Type 2 (KIF22)

KAP95

YLR347C

KPNB1

MDM38

YOL027C

LETM2, LETM1

PBS2

YJL128C

MAP2K7, MAP2K1, MAP2K2,
MAP2K5

SSK2

YNR031C

MAP3K4

SMP1

YBR182C

SWH1

YAR042W

NFI1

YOR156C

GLC7

YER133W

PPP1CC, PPP1CB, PPP1CA

TPK2

YPL203W

PRKX, PRKG2, PRKACB,
PRKACA, PRKG1, PRKACG

MEF2C, MEF2A, MEF2BNBMEF2B, MEF2B, MEF2D
OSBPL2, OSBPL1A, OSBP2,
OSBP
PIAS1, PIAS3, ZMIZ2, PIAS2,
ZMIZ1, PIAS4
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Renal Cell Carcinoma (RNF139)

Cardiofaciocutaneous Syndrome 3
(MAP2K1); Cardiofaciocutaneous
Syndrome 4 (MAP2K2)

Mental Retardation (MEF2C);
Coronary Heart Disease (MEF2A)

TPK3

YKL166C

PRKX, PRKG2, PRKACB,
PRKACA, PRKG1, PRKACG

ITT1

YML068W

RNF14

SAC3

YDR159W

SAC3D1, MCM3AP

SEC31

YDL195W

SEC31B, SEC31A

ULP2

YIL031W

SENP6, SENP7

SED5

YLR026C

STX5

SPT5

YML010W

SUPT5H

TOP1

YOL006C

TOP1MT, TOP1

TRM11

YOL124C

TRMT11

TRM5

YHR070W

TRMT5

TUB2

YFL037W

TUBB8, RP11-683L23.1, TUBB2B,
TUBB1, TUBB2A

STE4

YOR212W

WDR47, GNB5

RSP5

YER125W

WWP2, ITCH, NEDD4L, NEDD4,
WWP1

MSN5

YDR335W

XPO5

CTH1

YDR151C

ZFP36, ZFP36L1, ZFP36L2

TIS11

YLR136C

ZFP36, ZFP36L1, ZFP36L2

Polymicrogyria (TUBB2B);
Macrothrombocytopenia (TUBB1)

Syndromic Multisystem Autoimmune
Disease (ITCH)

Table 2: Dosage-sensitive yeast genes with human homologs and disease
associations
Dosage-sensitive yeast genes are listed with human homologs. Human homologs with
OMIM (Online Mendelian Inheritance in Man) annotated disease associations are given.
Human genes associated with the specific disorder are shown in bold if more than one
homolog exists for a yeast gene. Analysis performed by Oliver King.

2.2.4 Hsp104A503S Does Not Typically Rescue Dosage Sensitivity by Reducing
Protein Expression
One possible explanation for the broad-spectrum rescue of overexpression
toxicity was that Hsp104A503S simply reduced toxic protein expression. However,
previous studies established that Hsp104A503S rescues TDP-43 and α-synuclein toxicity
without affecting their expression level in yeast (207-210). Indeed, we confirmed that
Hsp104A503S rescued TDP-43 and α-synuclein toxicity without affecting their expression
level (Fig. 12A, B). However, we did observe a modest reduction in FUS expression by
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Hsp104A503S, which had also been observed previously (208). Thus, Hsp104A503S can
rescue toxicity of human neurodegenerative disease proteins without affecting their
expression, but would the same be true for the yeast dosage-sensitive proteins?
We analyzed the expression levels of 18 dosage-sensitive yeast proteins to
determine if Hsp104A503S was lowering toxic protein expression. Utilizing Gateway
cloning technology, dosage-lethal genes were inserted into a modified pAG413Gal-ccdb
destination vector with an N-terminal 6x hemagglutinin (HA) tag upstream of the gateway
cloning sequence. The HA-fusions were transformed into and expressed in BYV, BYW,
and BYA strains. 18 HA-fusions that produced growth phenotypes similar to that of
untagged protein were chosen for quantitative Western Blot analysis (Fig. 12A).
Although, curiously, addition of the HA tag to Glc7 enabled Hsp104 to rescue toxicity in
addition to Hsp104A503S (Fig. 12A). Triose-phosphate dehydrogenase, Tdh1, is not toxic
when overexpressed and was used as a control in the analysis (Fig. 12A). Hsp104A503S
coexpression with Tdh1 resulted in a slight (~12%), but not statistically significant,
decrease in protein expression (Fig. 12B). Of the dosage-sensitive proteins, 4 of 18
(Glc7, Bni4, Tbf1, and Fkh1) showed no decrease in expression in BYA compared to
BYV or BYW, indicating that Hsp104A503S can rescue toxicity without affecting toxic
protein expression level as with TDP-43 and α-synuclein (Fig. 12B) (207, 209, 210). 12
of 18 (Ppz1, Bik1, Hsf1, Kap95, Gip3, Skn7, Nam8, Ark1, Clb3, Swh1, Nab3, and Hms1)
dosage-sensitive proteins showed a slight to modest decrease in expression level (~1236%) in the BYA strain compared to the BYV control, but none of these differences were
statistically significant (Fig. 12B). Moreover, Hsp104 slightly to modestly reduced protein
expression level (by ~7-34%) to a similar extent as Hsp104A503S for five of these dosagesensitive proteins (Ppz1, Bik1, Kap95, Skn7, and Ark1), but conferred no rescue of
49

toxicity (Fig. 12A, B). Therefore, slight to modest reduction of protein expression level is
not sufficient to rescue toxicity in these cases. However, Hsp104A503S significantly
decreased expression of Akl1 (~60%) and Slk19 (~62%) compared to the vector and
Hsp104 controls (Fig. 12B). Thus, reduced protein levels of Akl1 and Slk19 by
Hsp104A503S could contribute to the reduction in toxicity. Furthermore, when the
decreases in expression of each gene was plotted against the suppression of toxicity by
Hsp104A503S, there was no correlation between the two variables (r2 = 0.0329), indicating
that decreased protein expression does not provide a general explanation for rescue of
toxicity by Hsp104A503S (Fig. 13). These studies indicate that typically Hsp104A503S does
not rescue overexpression toxicity by reducing protein expression.
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Figure 12. Hsp104A503S expression reduces the expression of some dosagesensitive genes.
A. N-terminal 6xHA tagged dosage-sensitive genes were transformed in yeast carrying
an empty vector or galactose-inducible Hsp104 or Hsp104A503S. The toxicity of untagged
dosage-sensitive proteins (left) was similar to HA-tagged (right) B. Expression levels of
HA-tagged dosage-sensitive proteins and human neurodegenerative disease-associated
proteins, α-Synuclein, TDP-43, and FUS were measured by Western blot analysis. αSynuclein was C-terminally tagged with 6x-HA, TDP-43 and FUS were untagged and
detected with antibody to endogenous epitope. Representative blots for the loading
control, Pgk1, and tagged protein, HA, are shown to the left. Quantification of the
Western blots are given to the right. HA-tagged protein expression normalized to the
vector control strain. Blue indicates decrease in expression, red indicates increase in
expression. (Mean ± s.e.m., n = 3-5 independent transformations, Two-way ANOVA
using Fisher’s LSD Test, * P< 0.05, ** P<0.01, black * only statistically significant
difference between BYV-BYA, red * statistically significant difference between BYV-BYA
and BYW-BYA).
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Figure 13. Hsp104A503S reduction of protein levels not correlated with suppression
of toxicity.
Scatter plot of HA-tagged protein toxicity suppression by Hsp104A503S expression versus
HA-tagged protein expression levels in the Hsp104A503S strain. The best-fit linear
regression is plotted in black.

2.2.5 Dosage-sensitive Proteins Do Not Form Amyloids in Yeast
A primary function of Hsp104 in yeast is to disaggregate proteins that accumulate
in amyloid structures and disordered aggregates (32, 172, 180, 243, 244). Thus, we
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assessed whether HA-tagged toxic proteins formed SDS-resistant amyloid structures,
and if Hsp104 or Hsp104A503S prevented their assembly. 4 of the 18 proteins tested
(Akl1, Hms1, Nab3, and Nam8) were among the top 179 candidates in a study that
identified yeast proteins with putative prion domains, a type of intrinsically disordered,
low-complexity domain enriched in glutamine, asparagine, tyrosine, and glycine residues
(245). However, none of these candidates formed bona fide prions in yeast (245). Using
semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) analysis with the
standard 2.0% SDS (Fig. 14) and lowered, less stringent 0.5% SDS (data not shown),
we did not detect the presence of high-molecular weight smears indicative of amyloid in
lysates from BYV, BYW, and BYA yeast expressing the dosage-sensitive proteins (Fig.
14). For Akl1, Hms1, Nab3, and Nam8 these findings were consistent with a previous
study, which also found these proteins did not assemble into SDS-resistant structures
detected by SDD-AGE (245). By contrast, the yeast prion protein, Rnq1, readily formed
these structures in wild-type yeast (Fig. 14). These results were not unexpected in the
vector control, which lacks endogenous Hsp104 that is essential in the formation and
maintenance of amyloid-based prion states in yeast (180). However, these findings
confirm that these proteins are not forming toxic amyloid conformers in yeast. Likewise,
the human neurodegenerative disease-associated proteins also did not require the
formation of amyloid to be toxic (Fig. 14). Thus, Hsp104A503S does not need to utilize its
amyloid-disaggregase activity to suppress the deleterious growth defect caused by
dosage-sensitive yeast genes, TDP-43, FUS, or α-synuclein.
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Figure 14. HA-tagged dosage-sensitive proteins do not form large, SDS-resistant
aggregates or amyloid.
Representative SDD-AGE of HA-tagged dosage-sensitive proteins expressed in yeast
with vector control (V), Hsp104 (W), and Hsp104A503S (A). The lack of a distinct high
molecular weight smears show that these proteins do not form SDS-resistant,
aggregated species consistent with amyloid formation. Rnq1-YFP readily formed SDSresistant, high molecular weight species in wild-type BY4741 yeast with Hsp104 (+), but
not in a BY4741 Δhsp104 strain (-) in which Hsp104 is disrupted.
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2.2.6 Hsp104A503S Coexpression Abrogates Aggregate Formation
Next, we assessed whether Hsp104A503S might prevent the formation of a less
stable, aggregated protein species to counter toxicity. Thus, we developed a filter
retention assays with milder conditions (0.1% SDS and 0.1% Triton X-100) than used for
SDD-AGE to determine if detergent-labile, less stable aggregates were formed in BYV
that were prevented or dissolved in BYA with Hsp104A503S expression. We used a
vacuum-based dot blot apparatus to apply the lysates to two consecutively stacked
membranes; first, a 0.2µm cellulose acetate (CA) membrane that trapped large
aggregates but allowed structures smaller than the pore size to pass through and bind to
the second nitrocellulose (NC) membrane underneath (Fig. 15).
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Figure 15. Filter Retention Assay.
The Filter retention assay was used to isolate, large aggregates formed in yeast. Lysates
from BYV, BYW, and BYA yeast expressing HA-tagged proteins were applied to two
stacked membranes: first, the 0.2µm cellulose acetate (CA) filter that traps large
aggregates but allows soluble proteins to pass through to the nitrocellulose (NC)
membrane.

We observed detectable aggregate formation (i.e. retention by the CA
membrane) by all dosage-sensitive toxic proteins in the BYV background (Fig. 16A, B).
Increasing the concentration of SDS to 2% with or without boiling the lysates resulted in
almost complete dissolution of aggregate species on the CA membrane (Fig. 17A, B).
Thus, in general these protein aggregates were not very stable and were detergent
soluble, indicating they are more likely to be more labile, disordered aggregates. The
57

only exceptions were Glc7, Bik1, Kap95, Nam8, and Gip3, which appeared to form some
aggregated structures that were SDS-resistant at room temperature (Fig. 17B).
Importantly, non-toxic proteins, Adh1, Amd1, and Tdh1 did not form aggregated
structures detected by this assay (Fig. 17C, D). Interestingly, Kar1, a dosage-sensitive
protein whose toxicity is not suppressed by Hsp104 or Hsp104A503S does not form
significant amounts of aggregated protein. However, in general, the presence of these
aggregated structures correlates with toxicity. Indeed, the toxic human
neurodegenerative disease proteins, TDP-43, FUS, and α-synuclein also formed
aggregated structures in the BYV background that were trapped by the CA membrane
(Fig. 16A, B).
Consistent with previous studies (207, 208), Hsp104 did not affect the
aggregation of TDP-43, FUS, and α-synuclein (Fig. 16A, B), and is unable to rescue
their toxicity (Fig. 5C). Likewise, Hsp104 did not significantly reduce the amount of
aggregated HA-tagged Glc7, Ppz1, Kap95, Gip3, Skn7, Bni4, Tbf1, Ark1, Fkh1, Clb3,
Akl1, Swh1, Kip1, Nab3, 14 of the 18 dosage-sensitive yeast proteins tested (Fig. 16A,
B). Hsp104 is also unable to rescue the toxicity of these proteins except for HA-tagged
Glc7 (Fig. 12A). Thus, the rescue of HA-tagged Glc7 toxicity by Hsp104 is likely not
related to alterations in Glc7 aggregation. Interestingly, Hsp104 significantly reduced the
aggregation of HA-tagged Bik1, Hsf1, Nam8, and Slk19 (Fig. 16A, B), but did not
suppress their toxicity (Fig. 12A). Thus, preventing aggregation to this extent alone
appears insufficient to eliminate toxicity for these proteins.
Consistent with previous studies (207, 208), Hsp104A503S prevented aggregation
of TDP-43, FUS, and α-synuclein (Fig. 16A, B), and rescued their toxicity (Fig. 12C).
Strikingly, Hsp104A503S also significantly reduced aggregate formation by 14 of 18
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dosage-sensitive proteins (Ppz1, Bik1, Hsf1, Gip3, Skn7, Tbf1, Nam8, Ark1, Fkh1, Clb3,
Swh1, Kip1, Nab3, and Slk19) compared to the vector control (Fig. 16A, B). It also
reduced aggregate formation by Glc7, Kap95, Bni4, and Akl1 (Fig. 16A, B), but here the
difference compared to the vector control was not statistically significant, although the
reduction in aggregates for Glc7 and Bni4 was significant compared to Hsp104 (Fig.
16A, B). Hsp104A503S rescued the toxicity of all of these HA-tagged proteins (Fig. 12A).
However, Hsp104A503S was unable to prevent the toxicity of HA-tagged Kar1 (Fig. 17C,
D), a highly toxic protein(246). Thus, aggregate dissolution may generally be utilized by
Hsp104A503S to suppress protein toxicity. Collectively, these findings indicate that rescue
of overexpression toxicity by Hsp104A503S is typically accompanied by a reduction in the
amount of toxic protein entering SDS-soluble aggregates.
With 6 of the 18 HA-tagged proteins, Glc7, Ppz1, Bni4, Fkh1, Clb3, and Kip1,
Hsp104A503S reduced aggregate formation significantly more compared to Hsp104 (Fig.
16A), confirming its enhanced activity compared to Hsp104. In all cases tested and
quantified, Hsp104A503S reduced aggregate formation more effectively than Hsp104 (Fig.
16A, B). Moreover, Hsp104 significantly reduced the aggregation of HA-tagged Bik1,
Hsf1, Nam8, and Slk19 (Fig. 16A, B), but did not rescue their toxicity (Fig. 8A). These
findings suggest that the mechanism by which Hsp104A503S prevents protein aggregation
to rescue toxicity is different from Hsp104, which can also impede the aggregation of
some toxic proteins but without alleviating toxicity (Fig. 12A, 16A, B). Thus, Hsp104A503S
may prevent the formation of particularly toxic aggregated structures, whereas Hsp104
only prevents the formation of benign aggregated structures and not toxic species. That
is, aggregates formed in the presence of Hsp104 possess a different toxic structure (or
‘strain’), whereas those formed in the presence of Hsp104A503S do not. The ability of
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Hsp104 to promote different ‘strains’ of protein aggregates with different phenotypic
properties (e.g. toxicity) has been observed previously in the context of Sup35 prions
(247) and polyglutamine aggregation (217). Alternatively, Hsp104A503S may also prevent
the co-aggregation of other proteins that contributes to toxicity, whereas Hsp104 may
not. Thus, aggregates formed in the presence of Hsp104 may sequester other essential
proteins and continue to confer toxicity. Further experiments are required to distinguish
between these possibilities.
Finally, it is also possible that Hsp104A503S exerts additional effects on soluble
forms of toxic proteins, which are not exerted by Hsp104. For example, Hsp104A503S may
disassemble toxic soluble oligomers, whereas Hsp104 may not. Alternatively,
Hsp104A503S may preferentially recognize the unfolded stretches of toxic proteins and
unfold, remodel, or otherwise inactivate the entire toxic protein, whereas Hsp104 may
not. Previous studies suggest that Hsp104A503V recognizes shorter unfolded segments of
proteins than Hsp104, and also promotes their rapid unfolding and inactivation in
situations where Hsp104 has no effect (207, 208). Thus, we anticipate that in addition to
preventing toxic aggregation, Hsp104A503S also has a direct effect on soluble forms of the
toxic protein, which contributes to rescue of toxicity.
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Figure 16: Hsp104A503S prevents aggregation of dosage-sensitive proteins.
A. The bar graph shows the quantification of aggregated protein detected by filter
retention assay as a ratio of aggregated (bound to the cellulose acetate) to flowthrough
soluble protein (bound to nitrocellulose). The values for the Hsp104 and Hsp104A503S
expressing strains were normalized to the vector control strain (Mean ± s.e.m., n = 3-5
independent transformations, Two-way ANOVA using a Fisher’s LSD Test, * P< 0.05, **
P<0.01, *** P < 0.0001, black * indicates statistical difference compared to BYV, red *
indicates statistical difference between BYV-BYA and BYW-BYA with number of * only
for BYV-BYA comparisons, P < 0.05 for all BYW-BYA comparisons, blue * indicates
statistical differences between BYW-BYA comparisons only). B. Representative filter
retention blots showing the aggregation state of HA-tagged proteins bound to the
cellulose acetate (CA) and nitrocellulose (NC) membranes in the vector control, Hsp104,
and Hsp104A503S strains.
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Figure 17. High concentrations of SDS or boiling dissolve aggregates of dosagesensitive proteins.
A. Representative filter assay using lysates boiled in sample buffer with 2% SDS at 99°C
for 5 minutes. B. Representative filter retention assay with lysates treated with 2% SDS
sample and incubated at 20°C for 5 minutes. C. Filter retention assay with non-dosagesensitive proteins (Adh1, Amd1, and Tdh1), which do not form aggregates in BYV, BYW,
or BYA strains. The non-suppressed dosage-sensitive protein, Kar1, also does not form
in BYV, BYW, or BYA strains. D. Spotting assays of BYV, BYW, and BYA yeast
expressing HA-tagged Adh1, Amd1, Tdh1, and Kar1.
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2.2.7 Defining Substrate Binding and ATPase Modalities Needed For Hsp104A503S
to Suppress Overexpression Toxicity.
To elucidate the mechanistic requirements for suppression of overexpressioninduced toxicity, we introduced several deactivating mutations to Hsp104A503S, targeting
the residues of Hsp104A503S critical for effective substrate binding and remodeling, as
well as ATP hydrolysis (Fig. 18A). Alanine substitutions to each of the two pore loops
tyrosines, Y257 (in NBD1) and Y662 (in NBD2), severely dampen substrate binding at
each pore loop and translocation through the central pore of Hsp104 (174, 248, 249).
Glutamine substitutions to each of the two Walker B motif glutamates, E285 (in NBD1)
and E687 (in NBD2), abolishes ATP hydrolysis but not binding, allowing the formation of
hexamers that can engage and bind substrate but not disassemble them (250). Thus, we
constructed seven Hsp104A503S variants to define substrate-binding and ATPase
modalities necessary to rescue overexpression toxicity: Hsp104Y257A:A503S (termed PL1,
‘pore loop NBD1’, which is dysfunctional in substrate binding to the NBD1 pore loop),
Hsp104A503S:Y662A (termed PL2, ‘pore loop NBD2’, which is dysfunctional in substrate
binding to the NBD2 pore loop), Hsp104Y257A:A503S:Y662A (termed DPL, ‘double pore loop’,
which is dysfunctional in substrate binding to the NBD1 and NBD2 pore loops),
Hsp104E285Q:A503S (termed WB1, ‘Walker B motif NBD1’, which is dysfunctional in ATP
hydrolysis at NBD1), Hsp104A503S:E687Q (termed WB2, ‘Walker B motif NBD2’, which is
dysfunctional in ATP hydrolysis at NBD2), Hsp104E285Q:A503S:E687Q (termed DWB, ‘Double
Walker B’, which is dysfunctional in ATP hydrolysis at NBD1 and NBD2), and
Hsp104Y257A:E285Q:A503S:Y662A:E687Q (termed DPL DWB, ‘Double Pore Loop Double Walker
B’, which is dysfunctional in substrate binding and ATP hydrolysis at NBD1 and NBD2).
These pore loop and ATPase Hsp104A503S variants were robustly expressed in Δhsp104
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yeast (Fig. 18B). These Hsp104A503S variants were screened against the dosagesensitive gene library.

Figure 18. Mutations of Hsp104A503S that reduce substrate binding and ATPase
activity are well expressed.
The Y257A and Y662A mutations inactivate the substrate-binding pore loops and the
E285Q and E687Q Walker B mutations prevent ATP hydrolysis but not ATP binding in
NBD1 and NBD2 respectively. A. On the structural model of Hsp104, the blue spheres
depict the location of the substrate-binding tyrosines along the central pore and the red
spheres the Walker B glutamates that bind ATP. B. Western blots of ∆hsp104 yeast
expressing Hsp104A503S pore loop and Walker B mutants show robust expression of all
seven mutants.
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As anticipated from previous studies on Hsp104A503V (251), rescue of toxicity of
the human neurodegenerative disease proteins, TDP-43, FUS, and α-synuclein, by
Hsp104A503S was severely impaired in PL1, PL2, DPL, DWB, and DWBDPL (Fig. 19).
However, WB1 and WB2 displayed partial ability to rescue (Fig. 19) (251). Thus, both
substrate-binding pore loops are critical for rescue of TDP-43, FUS, and α-synuclein
toxicity (251). By contrast, ATP hydrolysis at NBD1 or NBD2 is sufficient for partial
rescue of TDP-43, FUS, and α-synuclein toxicity, but ATP hydrolysis at both NBDs is
required for complete rescue (Fig. 19) (251). These findings suggest that the proteinremodeling activity, protein disaggregase activity, or both are required for Hsp104A503S to
rescue TDP-43, FUS, and α-synuclein toxicity in yeast (251).
For most dosage-sensitive yeast proteins, functional pore-loop tyrosine residues
and ATP hydrolysis by both NBDs were very important for full dosage suppression
provided by Hsp104A503S (Fig. 19). Interestingly, as with the human neurodegenerative
disease proteins, single Walker B variants of Hsp104A503S, WB1 or WB2, were partially or
fully active against diverse toxic proteins (Fig. 19). Thus, in many cases, ATP hydrolysis
at NBD1 or NBD2 is sufficient to rescue overexpression toxicity. By contrast, single poreloop variants, PL1 or PL2, were typically more inactivating and allowed the rescue of
relatively few toxic proteins (Fig. 19). As expected, the DPL, DWB, and DPLDWB
variants were almost completely inactive in rescuing overexpression toxicity (Fig. 19).
These findings suggest that the protein-remodeling activity, protein disaggregase
activity, or both are required for Hsp104A503S to rescue the toxicity of most dosagesensitive genes in yeast
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Figure 19. Pore loop and Walker B mutations greatly diminished Hsp104A503S
suppression of dosage-sensitive gene toxicity.
Spotting assay quantification of yeast co-expressing dosage-sensitive proteins and
Hsp104A503S mutants: Y257A (PL1), Y662A (PL2), Y257A:Y662A (DPL), E285Q (WB1),
E687Q (WB2), E285Q:E687Q (DWB), Y257A: E285Q: Y662A:E687Q (DPL DWB). Red
indicates increased toxicity, blue indicates increased rescue, yellow indicates increased
toxicity enhancement (n = 2-4 independent transformations).

When each variant is directly compared to Hsp104A503S for dosage suppression,
several notable features emerge. Alanine mutations to the individual substrate-binding
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tyrosines, PL1 (Y257A) and PL2 (Y662A), each almost completely abolished A503S
potentiation of Hsp104 (Fig. 20A, B). Of the 86 toxic genes that were suppressed by
Hsp104A503S by a score of 1 or more, only 11 of these genes were still suppressed by
that level when Y257A was introduced: RSP5, CHD1, KAP122, SFB3, PDS1, RTG3,
ASE1, NFI1, YDR306C, HSF1 and ECM9 (Fig. 20A, 21A, 22A). For Y662A, there are six
genes that fit this criteria: SEC31, CHD1, KAP122, HSF1, TUB2, and HSF1; and seven
genes for DPL: SEC31, KAP122, CHD1, PDS1, HSF1, ECM9, and YDR306C (Fig. 20B,
21A, 22A). PDS1, KAP122, HSF1, and CHD1 were the only genes rescued by all three
of the pore-loop variants (Fig. 20C, 21A, 22A). This strongly indicates that substrate
binding and especially the 662-position Tyrosine is crucial for Hsp104A503S potentiation,
and loss of substrate binding at either tyrosine effectively nearly ablates Hsp104A503Smediated suppression of dosage sensitivity. The few toxic proteins that were rescued by
PL1, PL2, or DPL variants might interact with the NTD of Hsp104A503S, which is also able
to engage substrates and plays a key role Hsp104 potentiation (189). Alternatively, the
rescue of these toxic proteins might be mediated by an indirect effect.
Intriguingly, single Walker B motif mutations, WB1 and WB2, were generally
much more effective at suppressing overexpression toxicity than the pore loop variants
(Fig. 19, 20D, E). Of the 86 toxic genes that Hsp104A503S suppressed by a score of 1 or
more, the WB1 mutants of Hsp104A503S suppressed the toxicity of 47 genes by a score of
1 or more and WB2 mutant suppressed 45 genes in the same manner. Surprisingly, the
set of genes suppressed are almost completely overlapping. 43 are suppressed by both
WB1 and WB2 (43 of 49 unique genes, 87.8%), with only BBP1, RPI1, STE4, and SUI1
uniquely rescued by WB1 and AFT2 and PAM1 suppressed only by WB2 (Fig. 21). This
remarkable result suggest that that certain substrates are specifically more amenable to
67

suppression by Hsp104A503S than others and that full ATPase activity is required for other
substrates. In the case of MHP1, ARK1, NFI1, and AKL1, these very toxic genes were
suppressed by both WB1 and WB2 nearly to the same extent as the fully ATPasecompetent version, Hsp104A503S (Fig. 22B). The DWB and DPLDWB strains show almost
no suppression of toxic genes in comparison to Hsp104A503S (Fig. 20F, G). Here too, any
suppression of toxicity likely stems from passive chaperone activity of the Hsp104A503S,
which could involve the pore loops and NTD for DWB, and likely just the NTD for
DPLDWB. The best-fit linear regression fit data from these scatter plots (Fig. 20)
illustrate the lack of suppression of PL1, PL2, DPL, DWB, and DPLDWB in preventing
dosage sensitivity and the relative robustness of WB1 and WB2 (Table 2). These data
suggest that the increased effectiveness of Hsp104A503S requires substrate binding to
both NBD pore loops and ATPase activity at both NBDs. However, Hsp104A503S activity
is more sensitive to mutations that disrupt substrate binding at either NBD than
mutations that disrupt ATPase activity at either NBD (251).
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Figure 20. Pore loop mutations more significantly decrease Hsp104A503S
potentiation than Walker B motif mutations.
Scatter plots of the suppression of each dosage-sensitive protein in Hsp104A503S (x-axis)
compared to suppression by each pore loop or Walker B variant in Hsp104A503S (y-axis):
A. Hsp104Y257A,A503S (PL1); B. Hsp104A503S,Y662A (PL2); C. Hsp104Y257A,A503S,Y662A (DPL); D.
Hsp104E285Q,A503S (WB1); E. Hsp104A503S,E687Q (WB2); F. Hsp104E285Q,A503S,E687Q (DWB);
G. Hsp104YY257A,E285Q,A503S,Y662A,E687Q (DPL DWB). The blue line in A-G corresponds to
y=1, i.e. suppression of toxicity of 1 in the mutant strains.
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Figure 21. Hsp104A503S with Walker B motif mutations suppresses dosage
sensitivity of many genes.
A heat map depicting the genes suppressed by single Walker B motif mutants of
Hsp104A503S (WB1 and WB2). Suppression is scored as in Figure 20 with blue indicating
increased rescue. Black boxes are for suppression scores below 1.

Table 3. Only single Walker B mutants of Hsp104A503S are consistent suppressors
of diverse dosage-sensitive genes.
The slope and coefficient of determination (r2) values based on the best-fit linear
regressions for the scatter plots shown in Figure 16 comparing Hsp104A503S suppression
of toxicity to each of the pore loop and Walker B motif mutants.
Notably, mutations to the pore loops and Walker B motifs were not only null in
suppressing toxicity of some dosage-sensitive genes, but actually enhanced toxicity of
many genes (Fig. 19, 20A-G). Even with the single Walker B Hsp104A503S mutants that
retain some rescue activity, 10-15% of genes fall below the x-axis indicating negative
suppression scores or enhanced toxicity (Fig. 20D, E). For the PL1, PL2, DPL, DWB,
DPL DWB Hsp104A503S mutants, the toxicity of up to 50% of genes was enhanced. Some
genes such as CDH1 exhibited greatly enhanced toxicity when co-expressed with PL1,
PL2, DPL, DWB, or DPLDWB, but were still rescued by WB1 or WB2 (Fig. 20A-G, 22C).
Other genes, such as CST6 exhibited greatly enhanced toxicity when co-expressed with
PL1, PL2, DPL, DWB, or DPLDWB, but toxicity was unaffected by WB1 or WB2 (Fig.
20A-G, 22C). These synthetic lethal phenotypes are intriguing and may stem from
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incomplete or partial remodeling of substrates to more toxic conformations by these
Hsp104 variants. Alternatively, these defective Hsp104A503S variants may hinder the
activity of molecular chaperones that would ordinarily engage these toxic substrates and
reduce toxicity.

Figure 22. Mutations of Hsp104 that reduce substrate binding and ATPase activity
diminish Hsp104A503S suppression of dosage-sensitive gene toxicity.
A. Representative serial dilution spottings show that despite mutations to pore loops the
toxicity of PDS1 and KAP122 were still partially suppressed. B. Single Walker B mutants
(WB1 and WB2) were still able to suppress the toxicity of 4 very toxic genes: MHP1,
ARK1, NF1, and AKL1. C. CDH1 and CST6 over expression were slightly toxic in the
vector, Hsp104, or Hsp104A503S strains, but in the PL1, PL2, DPL, DWB, and DPL DWB
strains these two genes were very toxic when expressed, showing an enhancement of
toxicity. WB1 and WB2, were able to provide partial rescue of toxicity for CDH1 and
CST6.
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2.2.8 Autophagy and Proteasome Activity Are Not Required for Hsp104A503S
Activity
Next, we sought to determine if the rescue of overexpression toxicity by
Hsp104A503S was due to increased activity of Hsp104A503S alone or whether it also
required downstream degradation pathways. We screened three yeast deletion mutants
in which autophagy and proteasome activities were perturbed to ascertain if Hsp104A503S
leveraged these pathways to inhibit proteotoxicity and if these deletions would affect
Hsp104A503S suppression. We disrupted the genes encoding Atg8, which is crucial for
autophagy induction and an essential component of autophagosomes (252-255), Rpn4,
a transcription factor that promotes proteasome gene expression, and deletion reduces
the level of the proteasome (256-258), and Ubr2, an E3 ubiquitin-ligase that targets
Rpn4 and promotes its degradation, which when deleted leads to increase proteasome
activity due to increase Rpn4 levels (259). Yeast with deletions or disruptions of ATG8,
RPN4, and UBR2 are viable and were used to screen the dosage-sensitive gene library.
The candidate genes were overexpressed in Δatg8Δhsp104 (autophagy-deficient),
hsp104Δubr2 (proteasome-induced), and Δhsp104Δrpn4 (proteasome-reduced) yeast
with Hsp104A503S or a pAG413Gal-ccdB vector control (Fig. 23).
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Figure 23. Dosage-sensitive protein toxicity and suppression by Hsp104A503S is not
typically affected in autophagy or proteasome-perturbed yeast strains.
ATG8, UBR2, and RPN4 were knocked out with HSP104 deletion were screened for
dosage-sensitive protein toxicity with a vector control and Hsp104A503S. Spotting assays
were quantified as in Figure 6 using the rubric in Figure 5B. Red indicates increased
toxicity, blue indicates suppression of toxicity in the ∆hsp104 background, and yellow
indicates enhancement of toxicity in the ∆hsp104 background (n = 2-4 independent
transformations).
Hsp104A503S suppressed the toxicity of TDP-43, FUS, and α-synuclein in the
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Δhsp104Δatg8, Δhsp104Δubr2, and Δhsp104Δrpn4 backgrounds. These findings are
consistent with previous studies that found Hsp104A503S suppression of TDP-43, FUS,
and α-synuclein toxicity did not require autophagy (207). We do observe a slight
enhancement of toxicity of several proteins in the double mutant strains, especially TDP43 and FUS in the Δhsp104Δrpn4 strain where proteasome activity is reduced, however,
rescue by Hsp104A503S is still robust (Fig. 23). Surprisingly, the Hsp104A503S-mediated
suppression of dosage sensitivity was generally unaffected by these genetic disruptions.
When the Hsp104A503S suppression of the toxicity of each gene in the autophagydefective and proteasome-perturbed yeast strains was plotted against Hsp104A503S
suppression of the same game in Δhsp104 yeast, the extent of suppression was
remarkably similar (Fig. 24A-C). The slopes of the linear regression fits for the
Hsp104A503S toxicity suppression in Δhsp104Δatg8, Δhsp104Δubr2, and Δhsp104Δrpn4
versus Δhsp104 were 0.806, 0.815, and 0.613 with coefficient of determination (r2)
values of 0.590, 0.596, and 0.402 respectively, indicating high concordance in rescue.
The lesser linear regression slope and correlation values for the Δhsp104Δrpn4 to
Δhsp104 strain comparisons indicate that proteasome function may have an effect on
gene toxicity itself because Hsp104A503S suppression is still very potent (Fig. 23). These
data suggest that neither autophagy nor the proteasome are strictly required for
Hsp104A503S to rescue overexpression toxicity.
Alterations to the autophagy and proteasome systems did slightly affect the
toxicity of genes in the Δatg8Δhsp104, Δhsp104Δrpn4, and Δhsp104Δubr2 strains
expressing just the empty vector. The slopes of the linear regression fit for the toxicities
of the dosage-sensitive genes in the Δhsp104Δatg8, Δhsp104Δubr2, and Δhsp104Δrpn4
strains compared to the Δhsp104 strain with only the vector control were 0.898, 0.908,
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and 0.738 with coefficient of determination (r2) values of 0.667, 0.665, and 0.432 for the
respective comparisons (Fig. 24D-F). These comparisons show that when proteasome
and autophagy pathways are affected, the basal toxicity of individual genes are generally
very similar to the Δhsp104 strain but with some variability. The slope of nearly 1 and
relatively high correlation for the Δhsp104Δatg8, Δhsp104Δubr2 plots indicate that gene
toxicity is generally very similar between these strains and Δhsp104. The decrease in the
correlation of the gene toxicity in the Δhsp104 and Δhsp104Δrpn4 comparison suggests
that proteasome activity reduction can have a substantial effect on the toxicity of the
genes when overexpressed (Fig. 24F). However, Hsp104A503S suppression of toxicity is
still very robust in Δhsp104Δrpn4 yeast (Fig. 23), indicating that Hsp104A503S can still
suppress the deleterious effects of dosage sensitivity even when proteasome function is
limited.
Some individual dosage-sensitive genes were significantly affected by ATG8,
UBR2, or RPN4 deletion. Some notable examples are CDH1 and CLB6, two genes
whose toxicity in the Δhsp104Δatg8 and Δhsp104Δubr2 background were enhanced
(Fig. 23, 24D, E, 25A). As expected, Hsp104A503S expression still robustly suppressed
the toxicity of CDH1 and CLB6 (Fig. 23, 25A). CDH1 toxicity was also increased in the
Δhsp104Δrpn4 yeast strain and likewise Hsp104A503S suppression of toxicity was still
effective, whereas CLB6 toxicity was unaffected when RPN4 was deleted. Curiously,
ITT1 and HSF1 toxicities were abolished in the Δhsp104Δrpn4 strain (Fig. 24F). Another
set of outliers are genes such as MRN1 and AKL1, which were less toxic when
overexpressed in Δhsp104Δatg8, Δhsp104Δubr2, and Δhsp104Δrpn4 strains (Fig. 23,
24E-F, 25A). As with CDH1 and CLB6, Hsp104A503S expression still rescued the dosage
sensitivity of MRN1 and AKL1 (Fig. 23, 25B). However, the toxicity of some genes was
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enhanced in the Δhsp104Δatg8, Δhsp104Δubr2 and Δhsp104Δrpn4 strains that
Hsp104A503S co-expression was not able to fully suppress (Fig. 23). Notably, Hsp104A503S
was not able to fully suppress toxicity of TPK3 and STE12 in the Δhsp104Δatg8 and
Δhsp104Δrpn4 backgrounds (Fig. 23, 24A, B, 25C); however, genes like TPK3 and
STE12 that are not suppressed were the rare exceptions. Overall, despite some
examples, these data indicate that Hsp104A503S is rectifying dosage sensitivityassociated toxicity directly and independent of autophagic and proteasomal function.
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Figure 24. Dosage-sensitive protein suppression by Hsp104A503S is not greatly
affected in autophagy and proteasome-perturbed yeast strains.
The suppression of dosage-sensitive protein toxicity by Hsp104A503S in hsp104Δ (x-axis)
plotted against Hsp104A503S suppression in A. Δ hsp104Δatg8 yeast; and B.
Δ hsp104Δrpn4 (y-axis). The toxicity of dosage-sensitive genes in the Δhsp104 (x-axis)
plotted against C. hsp104Δatg8 yeast; and D. Δ hsp104Δrpn4 (y-axis).

Figure 25. Toxicity of some dosage-sensitive genes are affected by deletion of
ATG8, UBR2, and RPN4.
Representative spotting assays of dosage-sensitive genes in Δatg8Δhsp104,
Δhsp104Δrpn4, and Δhsp104 yeast with vector control or Hsp104A503S. A. CDH1 and
CLB6 displayed enhanced toxicity in the Δhsp104Δatg8 and Δhsp104Δrpn4 strains
compared to Δhsp104 yeast. Hsp104A503S was still able to suppress the toxicity. B.
MRN1 and AKL1 both displayed a decrease of toxicity in the Δhsp104Δatg8
and Δhsp104Δrpn4 with the empty vector. C. The suppression of TPK3 and STE12
toxicity by Hsp104A503S was diminished in the Δatg8Δhsp104 and Δhsp104Δrpn4 strains.

2.2.9 Hsp104A503S Buffering Capacity Extends Beyond a Single Gene But Not To
Entire Chromosomes
Because of the tremendous ability of Hsp104A503S to suppress the toxicity of a
single overexpressed gene, we were inspired to determine the dosage-sensitive protein
buffering capacity of Hsp104A503S by simultaneously co-expressing multiple dosage79

sensitive genes in yeast. We selected four genes, AKL1, RSP5, MRN1, and SFB3, to
test in combination because of their differing toxicity scores and functions in the cell.
AKL1 is a serine-threonine kinase in the Ark1-family of yeast kinases that regulates actin
dynamics in cytoskeletal organization and endocytosis (260, 261). AKL1 was one of the
most toxic gene in the library with a highest score of 5 in BYV and BYW but no toxicity in
BYA (Fig. 6). RSP5 is an E3 ubiquitin ligase with many cellular functions in yeast, one of
which is its essential role in targeting proteins misfolded by heat shock for proteolysis
(261, 262). RSP5 only caused a mild growth defect with a score of 1.7 in BYV and no
toxicity in BYA (Fig. 6). MRN1 is an RNA-binding protein that interacts with chromatinremodeling complexes and is important for mRNA maturation in yeast (263, 264). MRN1
caused a moderate growth defect, score of 3.5, with full rescue by Hsp104A503S (Fig. 6).
SFB3 (formerly LST1) is a Sec24p-family protein that dimerized with Sec23p to form part
of the COPII vesicle coat that targets vesicles from the endoplasmic reticulum to the
Golgi, including those that contain large oligomeric proteins and difficult protein cargoes
(265, 266). SFB3 has moderate toxicity in BYV with a score of about 3 that is almost
completely suppressed in BYA (Fig. 6). We found that Hsp104A503S was indeed able to
suppress the toxicity of several pairs of co-expressed, unrelated, dosage-sensitive
genes (Fig. 21A). Toxic individually, the combinations of AKL1 + RSP5, MRN1 + RSP5,
SFB3 + RSP5, AKL1 + MRN1, and AKL1 + SFB3 were all very toxic to yeast expressing
the vector control or Hsp104, but expression of Hsp104A503S provided very robust
suppression of these five pair-wise combinations of dosage-sensitive genes (Fig. 26A).
These results indicate that Hsp104A503S can have the capacity to buffer the toxicity of at
least two genes simultaneously that have completely unrelated functions and possibly
different mechanisms of dosage sensitivity.
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Next, we tested whether Hsp104A503S could buffer growth defects in aneuploid
yeast strains bearing entire chromosomal duplications. In this way, we could determine if
there was an upper limit to the buffering capacity of Hsp104A503S. Specifically, we
employed yeast strains that contained discrete, characterized, single chromosome
duplications (267). However, Hsp104A503S expression was unable to suppress the toxicity
of most aneuploid strains despite only very mild growth defect caused by each additional
chromosome (Fig. 26B). Only against disome XII, did we observe a modest growth
enhancement by Hsp104A503S (Fig. 26B). Despite the ability to suppress the toxicity of
different pairs of unrelated genes, Hsp104A503S may not be able to suppress the growth
defect caused by a single extra chromosome. Thus, Hsp104A503S appears well equipped
to counter toxicity caused by the acute overexpression of one or two toxic genes.
However, Hsp104A503S is unable to buffer toxicity connected with a subtler upregulation
(~1.5-2-fold) in the expression of hundreds of yeast genes, with the possible exception
of chromosome XII.
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Figure 26. The buffering capacity of Hsp104A503S extends beyond single dosagesensitive genes.
A. Representative serial dilution spotting with two dosage-sensitive genes co-expressed
with an empty vector, Hsp104, or Hsp104A503S. Experiment performed by Courtney Buell.
B. Representative serial dilution spotting assays with disomic yeast strains co-expressed
with an empty vector, Hsp104, or Hsp104A503S. Experiment performed by Acacia Hori.

2.2.10 Some Catalytically-inactive Dosage-Sensitive Genes Lose Toxic Phenotype
To gain substrate-specific insight into Hsp104A503S dosage sensitivity
suppression, we focused on several toxic protein substrates for further analysis. We
sought to determine if the overexpression growth defect was connected to the enzymatic
activity of the toxic protein. Thus, we focused on protein kinases and phosphatases,
where it seems probable that excessive protein phosphorylation or dephosphorylation
due to overexpression could readily lead to regulatory defects and toxicity.
First, we focused on Ark1 and Akl1, which are members of the same family of
serine-threonine kinases that regulate actin cytoskeleton dynamics in yeast (260, 268).
The sequence identity in the kinase region of ARK1 and AKL1 is about 40%, with
divergent C-terminal regions that are implicated in regulation of function (260). The Cterminal regions of both proteins are predicted to be highly disordered and aggregationprone (Fig. 28C, D). Hsp104A503S rescue of Akl1 toxicity is accompanied by a reduction
on Akl1 expression and slightly reduced Akl1 aggregation (Fig. 12, 16), whereas
Hsp104A503S rescue of Ark1 is accompanied without an effect on protein expression but
with reduced Ark1 aggregation (Fig. 12, 16). However, was the kinase activity of Akl1
and Ark1 require for their toxicity?
We generated catalytically-inactive mutants of these dosage-sensitive kinases
Ark1K56A(260), and Akl1K78A(260) to determine if catalytic function was necessary for
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dosage sensitivity (Fig. 27A). Ark1K56A and Akl1K78A were not toxic when overexpressed
(Fig. 27B) despite high levels of expressed proteins (Fig. 29), demonstrating that kinase
activity is a necessary component of dosage sensitivity for these kinases. These findings
suggest that Hsp104A503S may also exert a direct effect on soluble Akl1 and Ark1, which
might reduce their kinase activity. Since Hsp104A503V can unfold soluble substrates that
bear an intrinsically unfolded domain, such as RepA-GFP (207, 208), we suggest that
Hsp104A503S might also unfold Akl1 and Ark1 to reduce kinase activity and rescue
toxicity. Further experiments are required to test this possibility.
Next, we focused on Glc7 and Ppz1, which are related serine-threonine protein
phosphatases with about 60% sequence identity in their catalytic regions (269). Ppz1
differs from Glc7 with a long stretch of amino acids in the N-terminal region of the protein
that is predicted to be unfolded natively but participates in interactions with binding
partners (Fig. 27A, 28A,B) (270). Hsp104A503S rescues toxicity of Glc7 and Ppz1 without
significantly affecting their expression level (Fig. 12), but does reduce their aggregation
(Fig. 16). However, was the phosphatase activity of Glc7 and Ppz1 needed for their
overexpression toxicity? To answer this question we generated Glc7H65K (271), and
Ppz1R451L (272) phosphatase-dead variants (Fig. 27A).
Ppz1R451L was robustly expressed but not toxic (Fig. 22B, 29), demonstrating that
Ppz1 phosphatase activity was critical for overexpression toxicity. Interestingly, Glc7H65K
was also robustly expressed but still toxic in BYV or BYW (Fig. 22B, 29). Thus,
phosphatase activity was not required for Glc7 toxicity. Despite being catalytically
inactive, Glc7H65K might still have the ability to form protein-protein interactions that are
deleterious to yeast that are possibly disrupted by Hsp104A503S. Indeed, perhaps the
aggregation of Glc7 (Fig. 16) is sufficient for toxicity, which is modestly reduced by
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Hsp104A503S. However, Hsp104 also rescues HA-tagged Glc7 and Glc7H65K toxicity (Fig.
12A, 27B), but does not affect aggregation of HA-tagged Glc7 (Fig. 16A). Thus, reduced
aggregation of Glc7 does not appear to be required for rescue of Glc7 toxicity. Perhaps
disruption of aberrant Glc7 protein-protein interactions by Hsp104A503S and aberrant HAtagged Glc7 protein-protein interactions by Hsp104 is critical to rescue toxicity. Further
experiments are needed to test this possibility.
Next, we explored whether the intrinsically disordered region of Ppz1 (Fig. 22A)
was required for Ppz1 toxicity. Thus, an N-terminal truncation mutant of Ppz1 (Ppz1Δ1344) was constructed to investigate the importance of the intrinsically disordered region
for dosage sensitivity. This unfolded region is also required for endogenous Ppz1
function (270). Ppz1Δ1-344 remained toxic in yeast (Fig. 27B), and thus the disordered
region was not essential for toxicity. Toxicity of this construct was reduced by
introduction of the R451L mutation, demonstrating that the phosphatase activity of Ppz1
is critical for toxicity (Fig. 27B). Hsp104A503S (but not Hsp104) rescued the toxicity of
Ppz1 and Ppz1Δ1-344 (Fig. 27B). Thus, the disordered region of Ppz1 is not required for
overexpression toxicity and is not required for rescue of toxicity by Hsp104A503S. We
suggest that Hsp104A503S might also target soluble Ppz1 to rescue toxicity, possibly
inhibiting phosphatase activity via binding site occlusion or forced unfolding. Increased
protein turnover or degradation was not a cause of loss of toxicity because protein
expression levels for Ppz1Δ1-344 and Ppz1Δ1-344R451L were substantial and consistent
between strains (Fig. 29).
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Figure 27. Deactivated dosage-sensitive proteins can lose toxicity.
A. Catalytically inactive versions of dosage-sensitive proteins, Glc7H65K, Ppz1R451L,
Ark1K56A, and Akl1K78A and truncation mutants, Ppz1Δ1-344 and Ppz1Δ1-344R451L, were
generated to determine importance of protein function to dosage sensitivity. B.
Representative serial dilution spottings with wild-type and null genes both untagged and
HA-tagged.
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Figure 28. Ppz1, Ark1, and Akl1 are all predicted to have large unfolded stretches.
FoldIndex prediction of the foldedness of a protein based on hydrophobicity and net
charge (273). Predictions are provided for A. Glc7; B. Ppz1; C. Ark1; and D. Akl1.
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Figure 29. Kinase- and Phosphatase-inactive proteins were expressed in Vector
control, Hsp104, and Hsp104A503S strains.
A. Representative Western blots of HA-tagged Glc7, Ppz1, Ppz1Δ1-344, Akl1, and Ark1
with the their respective null mutants in Δhsp104 yeast expressing an empty vector,
Hsp104, or Hsp104A503S. Pgk1 was used as the loading control.

2.2.11 Hsp104A503S Directly Decreases Ppz1 Phosphatase Activity in vitro
To determine if Hsp104A503S can target and deactivate soluble, active protein, we
purified Ppz1 from E. coli (274, 275) (Fig. 30A). We then assessed Ppz1 phosphatase
activity in the presence or absence of Hsp104 or Hsp104A503S. The phosphatase-dead
variant, Ppz1R451L, was also purified and used as a negative control for Ppz1 (Fig. 30A).
Purified Ppz1 and Ppz1R451L were mixed with purified Hsp104 or Hsp104A503S and paranitrophenyl phosphate (pNPP) substrate to determine Ppz1 phosphatase activity in
assay conditions similar to those used to test unfolding of RepA-GFP by Hsp104 (183)
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(Fig. 30B). pNPP is a chromogenic, artificial substrate for many phosphatases, including
serine/threonine phosphatases like Ppz1. Phosphatases hydrolyze the pNPP, liberating
a phosphate and leaving a para-nitrophenol that absorbs at 405 nm. Hsp104 incubated
with Ppz1 slightly decreased the activity of the phosphatase by approximately 15%
compared to Ppz1 alone. Remarkably, Hsp104A503S substantially decreased Ppz1 activity
by over 75% (Fig. 30B, C). Indeed, Ppz1 alone and Ppz1 incubated with Hsp104 had
activity levels that were within error, whereas, Ppz1 incubated with Hsp104A503S had
activity that was similar to the negative control, catalytically-inactive Ppz1R451L (Fig. 30B,
C). The in vitro inhibition of Ppz1 by Hsp104A503S demonstrates that there is a direct
interaction between Hsp104A503S with functional Ppz1 that is sufficient to decrease its
phophatase activity, which is necessary for dosage sensitivity.
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Figure 30. Hsp104A503S suppresses Ppz1 phosphatase activity in vitro.
A. Coomassie stain of E. coli purified Ppz1 and Ppz1R451L separated by SDS-PAGE. B.
0.7 µM purified recombinant Ppz1 was incubated with buffer control or 4mM ATP and
2.1 µM hexameric Hsp104, or Hsp104A503S. Phosphatase activity was measured with 10
µM pNPP substrate over the course of 15 minutes at room temperature in a microplate
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reader. Phosphatase activity of Ppz1R451L with 4 mM ATP was also measured.
Phosphatase activity normalized to Ppz1 activity at 15 minutes. (Mean ± s.e.m., n = 4
technical replicates). C. Phosphatase activity after 15 minute was normalized to Ppz1
activity in buffer control (Mean ± s.e.m., n = 4 technical replicates , one-way ANOVA
using Fisher’s LSD multiple comparisons test, **** = p < 0.0001).

2.2.12 Hsp104A503S Ablates v-Src Toxicity in Yeast
Based on the ability of Hsp104A503S to combat the toxicity of dosage-sensitive
genes associate with diverse neurodegenerative diseases as well as diverse dosagesensitive yeast genes, we investigated its ability to suppress the phenotype caused by
an overexpressed oncogene. Oncogenes are cancer-associated genes that are mutated
or misregulated, which often leads to hyperactivation or overexpression that can
contribute to malignancy. We employed v-Src, a Rous sarcoma virus gene encoding a
tyrosine kinase that is oncogenic in a variety of cell types chickens (276). However, in S.
cerevisiae, v-Src expression causes the opposite phenotype--stalled cell cycle
progression leading to large unbudded cells, presumably due to tyrosine phosphorylation
that is hypothesized to cause aberrant downstream signaling resulting in disruption of
mitosis (277, 278). v-Src is a specific client of Hsp90 chaperones, which interact with the
nascent v-Src protein to stabilize the protein, ensure proper folding, and insertion into
the plasma membrane, thus activating the protein (277). Deletion of yeast Hsp90 gene,
HSC82, abolishes v-Src toxicity, decreases v-Src expression levels, and decreases the
amount of tyrosine phosphorylation (277).
Remarkably, like with yeast dosage-sensitive genes, Hsp104A503S (but not
Hsp104) co-expression robustly suppressed the very severe v-Src growth defect (Fig.
31A). Unlike with most dosage-sensitive yeast genes, Hsp104A503S expression
significantly reduced the protein expression levels of v-Src by over 60% (Fig. 31B, C).
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Hsp104A503S overexpression also resulted in an approximately 40% decrease of
phosphotyrosines in yeast (Fig. 31D, E). These results mirror phenotypes observed in
yeast with HSC82 deletions, in which v-Src toxicity is also suppressed. Hsp104A503S
overexpression might act in a similar manner as HSC82 deletion, by directly opposing
the activity of Hsp90, which stabilizes, folds, and directs v-Src to the plasma membrane.
Thus, Hsp104A503S may remediate v-Src toxicity in yeast by unfolding or preventing the
folding of functional v-Src, which can then facilitate protease digestion. The reduction of
cytosolic v-Src, may then decrease the amount of potentially deleterious tyrosine
phosphorylation.
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Figure 31. Hsp104A503S suppresses v-Src toxicity and activity in yeast.
A. Representative serial dilution spotting with v-Src co-expressed with an empty vector,
Hsp104, or Hsp104A503S. B. Western blot detecting induced Hsp104 and v-Src protein
levels in Δhsp104 yeast expressing an empty vector, Hsp104, or Hsp104A503S. Pgk1 was
used as the loading control. C. Western blot detecting induced phosphotyrosine protein
levels in Δhsp104 yeast expressing an empty vector, Hsp104, or Hsp104A503S. Pgk1 was
used as the loading control. D. Quantification of Pgk1-normalized v-Src expression in the
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vector, Hsp104 and Hsp104A503S strains (Mean ± s.e.m., n = 4-6 independent
transformations and inductions, One-way ANOVA using Fisher’s LSD Test, **** = p <
0.0001). E. Quantification of Pgk1-normalized phosphotyrosine expression in the vector
control, Hsp104 and Hsp104A503S strains (Mean ± s.e.m., n = 4-6 independent
transformations and inductions, One-way ANOVA using Fisher’s LSD Test, *** = p <
0.001, **** = p < 0.0001).

2.3 Discussion
In this chapter, we show that Hsp104A503S displays unprecedented efficacy as a
suppressor of dosage sensitivity. Hsp104A503S suppressed the toxicity of the vast
majority, over 95%, of all genes tested, from the very toxic to those with more moderate
toxicity. We determined that Hsp104A503S was not simply depressing the protein
expression levels to rescue dosage sensitivity but likely had a more active role. We
found that while dosage-sensitive genes were not producing proteins that formed
amyloid, they did form large, SDS-soluble aggregates that were associated with toxicity.
Typically, Hsp104A503S was able to prevent the formation of these aggregates whereas
Hsp104 was not, although there were exceptions as discussed above. We probed the
ATPase and substrate binding modalities of Hsp104A503S and discovered that it is more
sensitive to mutations that impede substrate binding at either NBD than mutations that
disrupt ATPase activity at either NBD. Single mutations to either substrate binding loop
almost completely nullified Hsp104A503S potentiation, but mutations to Walker B motif
residues in individual NBDs were well tolerated. We revealed that Hsp104A503S
suppression of dosage sensitivity was not dependent on autophagy pathways or
proteasome function. By interrogating its buffering capacity, we found that Hsp104A503S
was able to suppress several combinations of two dosage-sensitive genes expressed on
different plasmids, but that it was ill equipped to counter the more subtle and systemwide proteome disruption caused by aneuploidy. To gain more granular insight into the
94

process by which Hsp104A503S prevents dosage sensitivity, we purified a dosagesensitive protein, Ppz1, and demonstrated that Hsp104A503S, but not Hsp104, could
greatly diminish Ppz1 phosphatase activity in vitro, which is essential for the toxic
overexpression phenotype in vivo. Lastly, we show that Hsp104A503S was able to robustly
suppress the toxicity of a potent oncogene, v-Src, and decrease the abundance of
protein and its activitt, which may restore proper cycle progression.
In totality, these finding establish Hsp104A503S as a potent suppressor of dosage
sensitivity in yeast. Without the aid of the autophagy and proteasome pathways,
Hsp104A503S disrupts aggregation formation and can directly inhibit protein activity to
rescue protein toxicity due to overexpression.
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CHAPTER 3: CONCLUSIONS AND FUTURE DIRECTIONS
3.1 Conclusions
We demonstrate that Hsp104A503S is an effective agent for combating toxicity
associated with protein overexpression. The suppression of over 95% of dosagesensitive genes by Hsp104A503S is unprecedented in scope. Of the 120 genes that had a
toxicity score above 0.75, Hsp104 rescued the dosage sensitivity of all but 3 genes,
KAR1, MUK1, and TRM5. Moreover, the effect of Hsp104A503S co-expression on dosage
sensitivity was extremely robust. Of the 48 moderate-to-high toxicity genes with scores
of 2.5 or above, Hsp104A503S reduced the toxicity of these genes by 2 or more for all but
2 genes, ITT1 and KAR1, proving that it is able to suppress toxicity of even the most
toxic genes.
We generated HA-tagged fusions to probe the expression and aggregation
phenotypes of the overexpressed, dosage-sensitive proteins in yeast when Hsp104,
Hsp140A503S, or a vector control was also expressed. Western Blot analysis showed that
although Hsp104A503S had a slight effect on protein expression, the extent of rescue was
not correlated to the decrease of protein expression. Thus, limiting the amount of protein
expressed was not the sole means of preventing protein overexpression toxicity.
Likewise, none of 18 dosage-sensitive proteins tested formed amyloid—although some
did form detergent-soluble, unstructured aggregates that were readily dissolved by
Hsp104A503S. The prevention or dissolution of these labile aggregates was correlated to
suppression of dosage sensitivity. In some cases, Hsp104 could reduce this aggregation
without affecting toxicity, which indicates that non-aggregated, soluble protein species
may be causing toxicity. Hsp104A503S, but not Hsp104, may be able to further denature
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these soluble toxic species—potentially through exposed hydrophobic regions that are
endemic to dosage-sensitive proteins, and a common modality for forming aberrant
inter-protein interactions that can lead to aggregation. This enhanced ability of
Hsp104A503S (compared to Hsp104) to unfold soluble substrates is a feature consistent
with previous studies (207, 208) and may be leveraged to prevent protein
overexpression-induced toxicity.
To determine if other cellular pathways were involved or necessary in the
Hsp104A503S suppression of dosage sensitivity we screened in several yeast knockout
mutant strains where autophagy and proteasome function were affected. Deletion of
ATG8, which disrupted autophagosome formation, UBR2, which induced proteasome
activity, and RPN4, which reduced proteasome function, did not alter that ability of
Hsp104A503S to suppress dosage sensitivity in yeast. Although the basal toxicity of some
dosage-sensitive proteins were affected in the autophagy-deficient and proteasomeperturbed strains, Hsp104A503S expression heartily suppressed dosage lethality in almost
all cases. These results strongly suggest that protein degradation pathways are not
adopted by Hsp104A503S to quell toxicity due to protein overexpression.
Next, we sought to elucidate the characteristics of Hsp104A503S that were most
important for its potentiation against dosage-sensitive proteins. Mutational analysis
showed that while substrate binding to pore loops was indispensable for Hsp104A503S to
rescue toxicity of diverse proteins, the potentiated protein was still very effective when
mutations to single NBDs ablated ATP hydrolysis. Moreover, mutations to the individual
NBD did not seem to greatly affect the repertoire of proteins that Hsp104A503S could
suppress. WB1 and WB2 variants could prevent the toxicity of an almost completely
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overlapping set of genes, indicating that perhaps certain protein substrates are less
taxing on Hsp104A503S, not requiring full activity.
We found that Hsp104A503S can attenuate the toxicity of at least two different
genes with different functions when they are overexpressed simultaneously. The robust
suppression of the combination of AKL1, one of the most toxic genes, and SFB3, a
moderate-high toxicity gene, was even more striking because two proteins are involved
in completely different processes and localized to different compartments in the cell.
Akl1, is a cytoplasmic kinase that is involved in actin cytoskeleton organization (261) and
Sfb3 is a part of the COPII vesicle coat assembly that targets vesicles from the ER to the
Golgi(265, 266). Yet even when both were overexpressed in the same yeast,
Hsp104A503S was able to suppress the toxicity of both genes.
To gain more insight into the mechanism of dosage sensitivity and how
Hsp104A503S may act to inhibit it, we generated and expressed inactivated versions of
several toxic genes. We showed that dosage sensitivity was dependent on the
enzymatic activity of Ppz1, Ark1, and Akl1. Thus, we wondered whether Hsp104A503S
might engage soluble toxic proteins and inactivate them, perhaps by forced unfolding as
with model RepA-GFP substrate (207, 208). We demonstrated that purified, functional
Ppz1 was inhibited by Hsp104A503S in vitro, significantly decreasing Ppz1 phosphatase
activity far more than Hsp104. Thus, Hsp104A503S can directly inhibit Ppz1. We suggest
that in addition to preventing formation of labile, SDS-soluble aggregates Hsp104A503S
can also suppress dosage sensitivity by directly unfolding or otherwise deactivating the
toxic protein.
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However, further experiments are needed to determine if Hsp104A503S is fully
unfolding Ppz1 to inactivate it or whether it is only partially engaging the substrate—
enough to sterically hinder the active site and thus inhibit phosphatase activity. The
potentially enlightening experiment would be to include with Hsp104A503S a modified
version of GroEL, GroELD87K, a ‘trap’ variant that can bind denatured substrates but not
release them due to its deficiency in ATP hydrolysis (279). Binding of Ppz1 to “trap” form
of GroEL would indicate that the phosphatase is indeed unfolded and will help clarify if it
is fully unfolded by Hsp104A503S. Likewise, the unfolding activity of Hsp104 can be
coupled to proteolytic degradation to demonstrate substrate translocation through the
central pore (280, 281). We can generate the HAP variant of Hsp104A503S, in which the
G739, S740, K741 residues are mutated to IGF, to foster physical interaction with the
bacterial protease, ClpP (249). In this complex, the Hsp104A503S-HAP would engage and
unfold substrate, directly translocating the substrate into the ClpP proteolytic chamber
where it is degraded into small peptide fragments (282). SDS-PAGE with Coomassie
staining or immunoblotting would provide a clear picture of whether Ppz1 was unfolded
by Hsp104A503S and degraded by ClpP. Pairing Hsp104A503S with either GroELD87K or
ClpP would provide more convincing evidence that Hsp104A503S is indeed unfolding toxic
substrates via polypeptide translocation.
Finally, we show that Hsp104A503S can even suppress the activity of a human
oncogene that is dosage sensitive in yeast. Although in chickens, v-Src promotes
oncogenesis, in yeast, it has the opposite effect of stalling cell cycle progression(278).
However, Hsp104A503S strongly suppressed this toxic phenotype in yeast. Thus proving
that in principle it (and perhaps other engineered protein unfoldases) may have
widespread applications in a variety of human diseases connected with protein
overexpression.
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Paradoxically, if Hsp104A503S is able to identify and unfold toxic, dosage-sensitive
substrates in nearly every instance, how does it avoid other soluble proteins? Hints of
this lack of specificity are present in the ever so slight defect in growth caused by
Hsp104A503S expression alone in the BYA strain, suggesting a basal level of Hsp104A503S
promiscuity in substrate selection which can be deleterious. This slight toxicity might
have exerted negative selection pressure for any amino acid at the 503 position but
alanine in yeast, which would explain why such a beneficial mutation against
overexpression toxicity was not adopted in yeast. Moreover, this mild toxicity is more
severe when yeast are grown at 37ºC and under mild thermal stress, whereas Hsp104 is
not toxic in these conditions. Our findings suggest that toxicity due to overexpression of
a single yeast gene is a rare form of stress, which may not have been a strong selective
force dictating Hsp104 sequence space. The inability for yeast to fully regulate internal
temperature makes them particularly susceptible to environmental changes that induce
protein-folding stress that could induce deleterious Hsp104A503S activity. These potential
off-target effects leading to a decrease in growth could be remedied by iterative
mutations of Hsp104A503S to derive variants with enhanced activity towards specific
substrates of interest, while limiting interactions with other substrates and thereby
eliminating the growth defect.
3.2 Future directions
The surprising efficacy of Hsp104A503S in combating nearly every dosagesensitive protein suggests that Hsp104A503S can potentially be leveraged to treat many
other diseases caused by protein overexpression. Beyond the use in treating
neurodegenerative disease such as AD, PD, HD, and ALS which feature accumulations
of aggregated protein, any disease in which protein regulation is lost and aberrant
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overexpression promotes disease pathogenesis would be a viable candidate for
treatment with Hsp104A503S. For example, many cancers feature overexpression of
protein including transcription factors, growth factors, and metabolic enzymes, all of
which could be targeted by Hsp104A503S for activity suppression. The promising result of
Hsp104A503S decreasing v-Src toxicity in yeast leads to the next steps of determining
whether it can be effective in cell culture and animal models of cancer to limit cellular
proliferation, return cells back to a more differentiated state, or counter oncogenic
phenotypes (reverse EMT, decrease telomerase expression, decrease colony formation,
restore contact inhibition, etc).
Yet, expressing Hsp104 in human patients is not without substantial challenges,
the primary of which is the high likelihood that expressing foreign yeast proteins in
humans would lead to a significant and potentially deadly immune response. Limited
expression of Hsp104 in the brain may be more easily tolerated due to Central Nervous
System (CNS) immune privilege, in which destructive, inflammatory T-cell responses
common in the periphery are dampened in certain areas of the CNS (283). The
effectiveness of Hsp104A503S in reversing cancer phenotypes presents an exciting proofof-principle to inform future work. If shown to be effective against models of cancer,
other proteins with lower immunogenicity such as human protein-remodeling factors or
unfoldases like Hsp70 and Hsp110 could be developed and engineered to gain activity
akin to Hsp104A503S in suppressing dosage sensitivity and prevent oncogenesis.
Retroviral delivery or CRISPR-Cas9 editing to introduce engineered human proteonremodeling factors to throttle the effects of overexpressed and aggregated protein in
targeted cell types would be an exciting next step.
Two chaperones that were tested in this study, Ssa1 and Hsp82, were not
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effective at suppressing protein overexpression toxicity. However, we only
overexpressed wild-type versions of these respective proteins with a moderate increase
in protein levels in a background that already feature substantial expression levels of
each. That neither wild-type Ssa1 nor Hsp82 were active against dosage-sensitive
proteins should not disqualify them for future studies because wild-type Hsp104 was
also unable to suppress dosage sensitivity in the same system. Rather, the results from
this study suggest that engineered mutants of Hsp82 or Ssa1 might be uncovered that
are effective against a wide spectrum of dosage-sensitive proteins. Moreover,
chaperones of the Hsp40 or Hsp110 families could be tested for elevated dosage
sensitivity suppression capacity. Like Ssa1 and Hsp82, Hsp40 and Hsp110 family
chaperones are also conserved in humans and any gains made in potentiating these
enzymes in yeast could be directly translatable to humans. Furthermore, these studies
would be particularly illuminating to determine the substrate recognition and binding
potential of these chaperones. It would be interesting to learn if engineered version of
these proteins also had a broad substrate repertoire like Hsp104A503S or if they were
narrower, tailored to specific substrates or classes of substrates.
In this study, Ppz1 phosphatase activity was shown to be essential for its dosage
sensitivity in yeast and we demonstrate that Hsp104A503S directly inhibited the
phosphatase activity of Ppz1 in vitro, which we proposed was the mechanism by which
Hsp104A503S curbed Ppz1 toxicity, but is this what actually happens cells? An interesting
next step would be to test to see if protein phosphorylation in yeast overexpressing Ppz1
was affected by coexpression of Hsp104A503S. A proteomics approach utilizing mass
spectrometry could accurately identify proteins whose phosphorylation state were
altered by Ppz1 expression and whether Hsp104A503S expression could affect the
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quantity or distribution of protein modifications. This would provide more direct evidence
that Hsp104A503S attenuation of Ppz1 activity in vivo was the mechanism by which it
suppressed Ppz1 toxicity. A phosphoproteomics approach could also be employed to
test the many other kinases and phosphatases that are dosage-sensitive (Fig. 10A) to
determine if the hyperactivity of these proteins are also abrogated by Hsp104A503S as a
means of limiting toxicity associated with overexpression of these proteins.
It is particularly interesting to note that not all members of a class of proteins are
dosage-sensitive. For example, in yeast, there are 3 members of the ARK1 kinase
family: ARK1, AKL1, and PRK1. Ark1 and Akl1 were two of the most toxic dosagesensitive proteins in our system. Despite sharing over 70% sequence identity with ARK1
in the kinase domain, having overlapping function, and similar architecture with an
intrinsically unfolded C-terminal region (268), PRK1 overexpression in our system was
not toxic. More than the isolated function of proteins must then determine dosage
sensitivity. Likewise, Ppz2 and Ppz1 are highly similar proteins, sharing 94% sequence
identity in the phophatase domain of the protein with 43% sequence identity elsewhere
and even boasting overlapping functions (269) and yet only Ppz1 is toxic when
overexpressed. How is it that genes with such similar functions and features, even
sharing high sequence homology could be drastically different in toxicity when
overexpressed? Characterizing the difference between Ppz1 and Ppz2 or Ark1 and Prk1
could reveal the factors that are most important for determining whether a gene is
dosage-sensitive. Moreover, understanding these differences could be useful in
determining how the deleterious effects of overexpression can be mitigated by cells with
or without potentiated Hsp104.
The toxicity of the main outliers in this study are also worthy of consideration.
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ITT1 and KAR1 are two very toxic genes that are almost completely resistant to
Hsp104A503S activity and TRM5 is a gene whose toxicity is enhanced by Hsp104A503S
expression. Of the 48 moderate-to-high toxicity genes with scores of 2.5 or above, ITT1
and KAR1 were the two genes that were not substantially rescued, although ITT1 toxicity
was slightly decreased by Hsp104A503S expression. ITT1 (Initiation of Translation
Termination) encodes a protein that can regulate the efficiency of translation termination
(284). Overexpression of ITT1 was shown to decrease the efficiency of translation
termination, presumably by increase binding to polypeptide chain release factors which
inhibits translation termination and results in significant increases in read-through of
nonsense and legitimate stop codons (284). The read-through of stop codons might lead
to the increase production of unfolded or misfolded proteins that exceeds the buffering
capacity of Hsp104A503S. Unlike with other dosage sensitive proteins, which Hsp104A503S
directly engage to suppress its deleterious effects, ITT1 overexpression may produce
misfolded substrates that Hsp104A503S bind instead of Itt1, leaving it to continue
promoting read-through of stop codons and the production of spurious protein products.
Indeed, Hsp104A503S was also typically unable to buffer toxicity conferred by aneuploidy,
which likely involves modest overproduction of hundreds of gene products. Explanation
for why the toxicity Kar1, a protein involved spindle pole body formation and duplication
during karyogamy and mitosis (285), is not rescued by Hsp104A503S is not as clear,
especially when so many of the other dosage-sensitive are also spindle pole body
components or otherwise involved in cell division. Likewise, how Hsp104A503S expression
enhances the toxicity of TRM5, which encodes a tRNA m1G37 methyltransferase (286),
is also not clear.
Is there a unifying theme to what makes genes toxic when overexpressed?
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Several studies hypothesize that dosage-sensitive proteins are involved in large
complexes with specific stoichiometry that is disrupted by overexpression (287), but that
theory has been largely discredited for dosage sensitivity caused by overexpression—
although it is still likely the cause of growth disruption for gene underexpression or
haploinsufficiency (42). The findings of this study suggest that some dosage-sensitive
proteins are toxic because its elevated enzymatic activity is deleterious and not the
result of a passive process such as the balance hypothesis would suggest (239, 288).
When mutated to the inactive form, Ppz1, Ark1, and Akl1 lost their dosage sensitivity
toxicity phenotype. This finding suggests that the normal function of some proteins is
essential for dosage sensitivity and Hsp104A503S can prevent this by decreasing protein
activity levels potentially though unfolding soluble protein (Fig. 32A).
Other recent studies also suggest that mass-action-driven interaction promiscuity
through interactions with intrinsically disordered regions within proteins is the most likely
explanation for the dosage sensitivity of overexpressed proteins. This theory is also
supported within the context of our hyperactivity model because aberrant interactions
with catalytically active dosage-sensitive proteins may result in detrimental
consequences. For example, Ppz1 has an intrinsically unfolded N-terminal region that is
essential for protein function which can be myristoylated and is thought to be important
for forming protein-protein interaction to specify function (270). Overexpression of Ppz1
could lead to overwhelming the regulation of this protein, especially in the intrinsically
unfolded region, resulting formation of unregulated promiscuous interactions with nonnative client proteins. Ppz1 may then dephosphorylate non-canonical regulatory sites
resulting in unwanted activation or inhibition of crucial enzymes. However, we found that
this region of Ppz1 was not required for overexpression toxicity. Nonetheless, the high
105

enrichment of intrinsically unfolded regions and linear motifs in dosage-sensitive proteins
is a likely modality for these toxic proteins to form deleterious protein-protein
interactions.
Exposed disordered regions in dosage-sensitive proteins provide low specificity
binding surfaces that could also foster aberrant and promiscuous interactions that can
lead to toxic aggregate or oligomer formation, sequestration of essential proteins through
non-native interactions, diversion of chaperones, and even formation of liquid-liquid
phase separations (LLPS). Hsp104A503S is well adapted to also tackle each of these
possibilities. Hsp104A503S was shown to be very effective (much more so than Hsp104) at
dissolving dosage sensitivity-associated protein aggregates in cells and also in vitro (Fig.
12A, B) (207, 208), so if dosage-sensitive proteins were forming aggregates,
Hsp104A503S would be more capable of dissolving them (Fig 32B). Moreover, the
enrichment in linear motifs and intrinsically disordered regions in dosage-sensitive
proteins, which can cause toxic oligomer or aggregate formation, can also facilitate
promiscuous interactions with non-native binding partners and even trapping these
proteins within aggregated structures. Hsp104A503S can mediate the release these
speciously bound proteins by disrupting oligomeric complexes and dissolving
aggregates (Fig. 33C). However, if dosage-sensitive proteins are diverting other
molecular chaperones from their intended substrates, Hsp104A503S can provide an
additional buffer for these toxic proteins (Fig. 33D). Hsp104A503S is capable of refolding
aggregated and denatured substrates, even without collaboration of Hsp40 and Hsp70
co-chaperones in vitro (207, 208), its elevated activity against misfolded and
aggregation-prone substrate, would unencumber the proteostasis network.
Lastly, the intrinsically-disordered regions endemic to dosage-sensitive proteins
could be undergoing inappropriate and toxic LLPS (160). Indeed, in addition to the high
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propensity of these toxic proteins to have intrinsically-disordered regions compared to
the genome, another highly common feature are prion-like domains (Fig. 11A). Prion-like
domains feature high polar uncharged amino acid and glycine content (289), which can
also drive LLPS (157, 158, 290-292). Recent work has shown that for the dosagesensitive protein, Mip6, toxicity was correlated with induction of a LLPS and growth was
restored when the foci were dissolved (160). This work suggest that SDS-soluble
aggregates we detected in the filter retention (Fig 16A, B) may actually be labile, phaseseparated liquid aggregates and Hsp104A503S was able to suppress the toxicity of these
proteins by fully dispersing these droplet structures, which may be correlated with
toxicity (Fig. 32E).
The ability for Hsp104A503S to suppress the toxicity of nearly every dosagesensitive gene opens up the possibility that Hsp104A503S can be used to treat many
human diseases in which increased gene dosage can be a contributor to disease
pathology. Moreover, the multitude of potential mechanisms by which Hsp104A503S can
employ to overcome proteotoxicity in diseases in which proteostatic integrity is lost,
provides great flexibility in its application to treat neurodegenerative disease such as AD,
PD, HD, and ALS. Further study will be required to determine whether or not
Hsp104A503S or related engineered proteins can be translated in clinical settings to
provide lasting impact in treating human diseases.
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Figure 32. Hsp104A503S may suppress dosage sensitivity in many distinct ways.
A. A protein can cause dosage sensitivity when overexpression leads to decreased
regulation and in increased activity of the protein resulting be spurious and off-target
effects. Hsp104A503S may bind the overexpressed toxic protein through exposed
disordered regions, unfold it, and reduce deleterious activity. B. Some proteins when
overexpressed will form oligomeric species or aggregates that have a toxic gain-offunction. Hsp104A503S can bind and dissolve these oligomers and aggregates to allow
them to refold to their native form. C. Dosage sensitive proteins are enriched in linear
motifs and intrinsically-disordered regions, which may be able to form low specificity,
promiscuous interactions with non-native binding partners or trap essential proteins in
aggregates. Hsp104A503S can unfold these misfolded proteins and release their binding
partners. D. Dosage sensitive proteins can also have the indirect effect of diverting other
molecular chaperones from their intended substrates. Hsp104A503S can provide an
additional buffer for these proteins that are misfolded and aggregation-prone, thereby
empowering the proteostasis network. E. The intrinsically disordered regions and prionlike domains enriched in dosage-sensitive proteins can also form intermolecular
interactions to drive LLPS events that are correlated with dosage sensitivity. Hsp104A503S
can mediate the dispersion of these phase-separated droplets.
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CHAPTER 4: METHODS
4.1 96-well Plate Yeast Transformation
Modified from published protocols (293). 250-500 ng of selected plasmid DNA
from the FLEXgene library (~5,500 genes and ORF’s in a galactose-inducible
expression pBY011 plasmid system, (294)) were individually plated into the wells of 96well cell culture plates (Denville T1096). For each 96-well plate of DNA to be
transformed into yeast, 200ml of YPD were inoculated with an overnight culture of yeast
at OD600 of 0.1 and grown with shaking (250 rpm for all steps) at 30 ºC until OD600
measured 0.8-1.0. Yeast cultures were pelleted by centrifugation (5 minutes at 1500 g
for all steps), supernatant was decanted, and the pellet was resuspended in 10 ml of
sterile water. The yeast slurry was pelleted by centrifugation, washed in 0.1 M lithium
acetate (LiOAc) in TE (10 mM Tris, pH 7.5 and 1mM EDTA) and pelleted by
centrifugation. The yeast was then resuspended in 7ml 0.1M LiOAc/TE and incubated
for 15 minutes with shaking at 30 ºC. β-mercaptoethanol was added to a final
concentration of 0.1M and incubated for 15 minutes with shaking at 30 ºC. Boiled and
chilled, sonicated salmon sperm (Agilent 201190) was added to yeast slurry to 3% final
concentration. 50 µl yeast slurry was dispensed into to each well by multichannel pipette
or liquid handling robot. 125 µl transformation mix (0.1M lithium acetate, 40% PEG 3350,
10% DMSO) was added to each well by multichannel pipette or liquid handling robot,
mixed thoroughly, and then the plates were incubated for 30 minutes at room
temperature. Yeast were then heat shocked for 30 minutes at 42 ºC and pelleted by
centrifugation. The PEG solution was forcefully decanted over a liquid waste receptacle
and 100 µl appropriate selective, synthetic media supplemented with glucose was added
to each well. Yeast were pelleted by centrifugation, the supernatant was decanted, and
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200 µl synthetic media supplemented with glucose was added to each well. Plates were
incubated for 48 hours at 30 ºC to allow for selection and growth of transformed yeast.
Small white yeast colonies should be visible at the bottom of each well.
4.2 Yeast Spotting Assays
Transformed yeast were resuspended by vigorous pipetting and 5-10µl
suspension was added to raffinose-supplemented synthetic media in 96-well tissue
culture plates (200 µl per well) then grown overnight at 30°C without shaking. Cultures
were 5-fold serially diluted into new 96-well tissue culture plates with sterile water and
spotted using a 96-bolt blot replicator (V&P Scientific Cat. No. VP 404) onto 2% agarsolified synthetic media with glucose or galactose in Omnitrays (Thermo 242811). Plates
were grown inverted for 2 days at 30°C or 3 days at room temperature, photographed
with a Canon SD1200 IS digital camera on an enlargement stand, and scored by the
scale given in Fig. 1B.
4.3 Analysis of Dosage-sensitive Gene Features
Dosage-sensitive gene functions (Fig. 10A, B) and component Gene Ontology
(GO) terms were obtains using the SGD Gene Ontology Slim Mapper
http://yeastgenome.org/cgi-bin/GO/goSlimMapper.pl
Dosage sensitive gene feature enrichment correlation (Fig. 11A) was performed
by Oliver King as described (4). Briefly, for each feature tested, the correlation was
determined for the gene to that feature. A tenfold cross-validation experiment was used
to determine the predictiveness of each feature to the dosage-sensitive genes. The
mean area under a receiver operating characteristic (ROC) curve for each of the cross-

111

validation experiments was used to determine the enrichment of each feature in the
dosage-sensitive gene set. The following features were used:
•

From the SGD table protein_properties.tab, but with counts of each AA changed
to percentages, to remove most (but maybe not all) of their correlation with
PROTEIN.LENGTH:
o PI (isoelectric point)
o CAI (codon adaptation index (codonw.sourceforge.net))
o PROTEIN.LENGTH (number of AAs in protein)
o CODON.BIAS (codon bias index (codonw.sourceforge.net))
o PCT.ALA
o PCT.ARG
o PCT.ASN
o PCT.ASP
o PCT.CYS
o PCT.GLN
o PCT.GLU
o PCT.GLY
o PCT.HIS
o PCT.ILE
o PCT.LEU
o PCT.LYS
o PCT.MET
o PCT.PHE
o PCT.PRO
o PCT.SER
o PCT.THR
o PCT.TRP
o PCT.TYR
o PCT.VAL
o FOP.SCORE (frequency of optimal codons (codonw.sourceforge.net))
o GRAVY.SCORE (hydropathicity of protein)
o AROMATICITY.SCORE (Frequency of aromatic amino acids: Phe, Tyr,
Trp)
o VERIFIED (1 if Verified, 0 if Uncharacterized or Dubious ORF)

•
•
•
•
•
•
•
•
•
•

PRD.LLK (Prion-like AA comp score form earlier version of PLAAC)
FInumaa (FoldIndex: number of disordered residues)
FImeanhydro (FoldIndex: mean hydropathy score)
FImeancharge (FoldIndex: mean charge)
FImeancombo (FoldIndex: disorder score for whole protein)
FImaxrun (FoldIndex: longest run of consecutive disorder)
IUcount (IUpred: number of disordered residues)
IUmaxrun (IUpred: longest run of consecutive disorder )
IUmean (IUpred: mean of per-residue disorder scores)
ANCHORcount (ANCHOR: number of disordered binding regions)
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•

ELMcount (number of Eukaryotic Linear Motifs)

•

1 for Gene Ontology membership in following categories, 0 otherwise
o GO.regulation.of.biological.process (GO:0050789)
o GO.transcription (GO:0006350)
o GO.signaling (GO:0023052)

•

From BIOGRID 2.0.5.29
o Essential (1 if gene deletion is toxic (need ref; hom or het?))
o y2h.total (total number interactions by Y2H (from BIOGRID 2.0.5.29))
o y2h.unique (number of distinct proteins with Y2H interaction)
o y2h.essential.total (total number of interactions with essential proteins by
Y2H)
o y2h.essential.unique (number of distinct essential proteins with Y2H
interaction)
o count.het.sensitive (number of conditions in which heterozygous deletion
was sensitive)
o count.hom.sensitive (number of conditions in which homozygous deletion
was sensitive (ref?))
o TAP.FILTERED (protein filtered out from TAP interactome (for being too
sticky?)
o count.sga.hits (number of synthetic genetic associations (Costanzo and
Boone 2009)
o sga.universe (if part of universe of tested genes in above study)
o HAS.HUMAN.ORTH (1 if protein had human ortholog, 0 otherwise)
o HAS.DISEASE.ORTH (1 if protein had human ortholog associated with
OMIM disease, 0 otherwise)

•

The following features are from Vavouri et al Cell 2009
http://www.cell.com/cms/attachment/604186/4784523/mmc1.pdf
o Dosage.sensitive
## Toxic due to overexpression in Sopko et al 2006
o Intrinsic.Disorder..GlobPlot.
o Intrinsic.Disorder..DisEMBL.REM.
o Intrinsic.Disorder..DisEMBL.COILS.
o Number.of.binary.protein.interactions
o 5..UTR.length..bp.
o Translation.rate
o Upstream.conservation..fraction.
o Transcription.rate
o Protein.half.life..mins.
o Upstream.noncoding.region..bp.
o mRNA.half.life..mins.
o Protein.abundance
o Aggregation.load
o 3..UTR.length..bp.
o Aggregation.score..TANGO.score.
o Responsiveness
o Noise..DM.
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o
o
o
o
o
o
o
o
o

Aromaticity.score
Expression.divergence
Recombination.rate
Number.of.protein.complex.interactions
Frequency.of.optimal.codons
mRNA.abundance
Codon.bias
Ka.Ks
Underwrapping

4.4 Immunoblotting
Yeast were grown to logarithmic growth phase in synthetic media with raffinose,
then pelleted by centrifugation, resuspended in galactose-containing media, and
incubated overnight (16 hours) at 30 ºC with rotation. Cultures were pelleted, washed
with sterile water, and treated with 0.05 M NaOH for 10 min at room temperature. Yeast
suspensions were pelleted and then resuspended in sample buffer (60mM TrisHCl, pH
6.8, 5% glycerol, 2% SDS 200, 4% beta-mercaptoethanol, 0.0025% bromophenol blue)
and boiled for 5 minutes. Cleared lysates were separated by SDS-PAGE (Bio-Rad Cat.
No. 3450010 Criterion Tris-HCl Precast Gels, 4–20% gradient) and transferred onto a
PVDF membrane (EMD Millipore IPFL00010 Immoblilon-FL) by semi-dry transfer (BIORAD Cat. No. 1703940). Membranes were blocked (Odyssey 927-40000 PBS Blocking
Buffer) overnight at 4’C. Primary antibodies were diluted in blocking buffer and incubated
with blots for 1 hour at room temperature with rocking. Blots were washed 4 times for 10
minutes in PBS-T (0.01 M phosphate buffer, pH 7.4, 0.0027 M potassium chloride, 0.137
M sodium chloride, 0.1% Tween-20) and incubated with secondary antibodies for 1 hour
at room temperature with rocking. Blots were washed 4 times for 10 minutes in PBS-T,
twice for 5 minutes in PBS. Blots were visualized using LI-COR Odyssey Model 9120 or
Fc Imaging systems and analyzed with LI-COR Image Studio software.
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Antibodies used were:
•
•
•
•
•
•
•
•
•
•
•

anti-Hemagglutinin (HA) monoclonal (Roche 11583816001, 0.4µg/ml final
concentration)
anti-Hsc82 (Abcam ab30920, 1:1000)
anti-Hsp70 (Abcam)
anti-TDP-43 polyclonal (Proteintech 10782-2-AP, 1:1000)
anti-FUS polyclonal (Bethyl A300-302A, 1:2000)
anti-Hsp104 polyclonal (Enzo Life Sciences ADI-SPA-1040, 1:1000)
anti-3-phosphoglycerate kinase (Pgk1) monoclonal (Novex Part# 459250,
1:1000)
anti-Src antibody (Abcam ab16885, 1:250)
anti-phosphotyrosine (Millipore 05-321, 1:1000)
IRDye680RD Donkey Anti-Rabbit (LICOR 926-68073, 1:7500)
IRDye800CW Donkey Anti-Mouse (LICOR 925-32212, 1:7500)

4.5 Semi-denaturing Detergent Agarose Gel Electrophoresis (SDD-AGE)
SDD-AGE was conducted with modification as reported (Halfmann, JoVE 2008).
The HA-tagged proteins were transformed into BYV, BYW, and BYA yeast.
Transformants were grown in Raffinose-containing synthetic media to logarithmic growth
phase in 96-well deepwell plates (Eppendorf Cat. No. 0030502302), then yeast were
pelleted by centrifugation (1500 g for 5 minutes) and resuspended in Galactosecontaining synthetic media at an optical density (OD600) of 0.100. Following overnight (16
hour) induction, yeast were pelleted by centrifugation, washed with sterile water,
pelleted, and then resuspended in spheroplasting solution (1.2 M D-sorbitol, 0.5 mM
MgCl, 220 mM Tris, pH 7.5, 50 mM β−ME and 0.5 mg/ml Zymolyase 100T) and
incubated for 1 hour at 30˚C with occasional shaking to keep the yeast suspended in
solution. Spheroplasts were pelleted by centrifugation (500 rcf for 5 minutes) and
resuspended in lysis buffer (100 mM Tris, 7.5, 500 mM NaCl, and 1% Protease Inhibitor
cocktail (Sigma P8215), 2mM EDTA, and 2mM PMSF). The suspensions were vortexed
at high speed for 1 minute and then snap-frozen in liquid nitrogen. 4X sample buffer (2X
TAE, 20% glycerol, 2 or 8% SDS, 10% β−ΜΕ, and 0.0025% bromophenol blue) was
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added to lysates and incubated for 5 minutes at room temperature. Samples were
loaded onto a 1.5% Agarose gel in 1X TAE and 0.5% or 2% SDS in a horizontal slab
electrophoresis apparatus tray. Samples were run at 5 V per cm of terminal distance in a
4 ºC cold room until dye front was 1.5 cm from the end of the gel. The samples were
then transferred by vertical capillary action overnight onto a nitrocellulose membrane as
reported (Halfmann, JoVE 2008). The membranes were blocked overnight in Licor
Blocking Buffer and then incubated with anti-HA monoclonal primary diluted in blocking
buffer (1:1000) for 1 hour, washed 4 times in PBS-T for 10 minutes each, incubated with
anti-Mouse IRDye 800CW secondary antibody in blocking buffer (1:7500) for 1 hours,
washed 4 times for 10 minutes in PBS-T, twice for 5 minutes in PBS. Proteins were
detected LI-COR Odyssey Models 9120 and Fc and analyzed with LI-COR Image Studio
software.
4.5 Filter Retention Assay
Lysates from yeast expressing HA-tagged proteins were prepared as for SDDAGE. 4X sample buffer (2X TAE, 20% glycerol, 0.4% SDS, 10% β−ΜΕ, and 0.0025%
bromophenol blue) was added to lysates and incubated for 5 minutes at room
temperature. Samples were applied onto two stacked membranes using a Minifold I 96
well spot-blot array system (GE Healthcare 10447850): on top, the 0.2µm pore size
cellulose acetate (Whatman OE66 Cat No. 10404129) that bound large aggregates with
0.45µM nitrocellulose membrane (Thermo 88018) below to bind protein flowthrough. A
piece of Whatman 3MM CHR (GE Healthcare 3030-221) filter paper was placed on the
bottom of the stack to facilitate sealing of each well. 20-100 µl of prepared lysates were
applied directly to the membranes. Care was taken not to over load the membranes and
thus disrupting flow of sample and wash buffer through the membrane. While still in the
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spot-blot apparatus, each sample well on the membrane was washed three times with
200 µl PBS-T. The blots were removed from the apparatus and washed again with PBST for 10 minutes with rocking and then blocked with Odyssey Blocking Buffer (PBS)
overnight at 4 ºC with rocking. Next, the blots were incubated with anti-HA monoclonal
primary diluted in Licor Blocking Buffer (1:1000) for 1 hour at room temperature with
rocking. After four 10-minute washes in PBS-T with rocking, membranes were incubated
with anti-Mouse IRDye 800CW secondary antibodies in Licor Blocking Buffer (1:7500)
for 1 hour at room temperature with rocking. Membranes were washed 4 times for 10
minutes in PBS-T, twice for 5 minutes in PBS, all with rocking, and finally visualized
using LI-COR Odyssey Model 9120 or Fc Imaging systems and analyzed with LI-COR
Image Studio software.
4.6 Generation of yeast deletion strains (with Korrie Mack)
PCR-based gene disruptions was performed to knockout Hsp104 from BY4741based atg8Δ and rpn4Δ yeast strains (Dharmcon YSC6273-201930575, YSC6273201935103, YSC6273-201921616 respectively). Forward and reverse primers were
designed with 5’ overhangs that were complementary to the ORF of the Hsp104 gene
and a 3’ section that were complementary to Hygromycin B phosphotranferase gene.
PCR-amplification was used to produce a DNA fragment that was transformed into yeast
that utilized homologous recombination to replace the Hsp104 ORF with the Hygromycin
B phosphotransferase gene. Transformants were plated on YPD agar with 300 µg/ml
Hygromycin B to select for yeast with the gene insertion. PCR was used to confirm gene
disruption and Western blot analysis used to determine loss of Hsp104 expression.
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4.7 Ppz1 Protein Purification
GST-PPZ1 and GST-PPZ1R451L were purified from BL21-CodonPlus(DE3)-RIL E.
coli (Agilent Cat. No. 230245) as reported with modifications (275). Briefly, bacteria
transformed with the pGEX6P1-PPZ1 or pGEX6P1-PPZ1R451L were grown in LB with 0.5
mM MnCl2 at 37 ºC with rotation overnight. The following day, the cultures were diluted
in LB with 0.5 mM MnCl2 and incubated at 37 ºC with shaking (250 rpm) to OD600 0.4.
Cultures were then chilled to 15 ºC and induced with 0.5 mM IPTG overnight,
approximated 16 hours. Cells were pelleted by centrifugation, resuspended in 10 pellet
volumes sonication buffer (50 mM Tris-HCl, pH 7.5, 0.2 mM EGTA, 150 mM NaCl, 10%
glycerol, 0.1% Triton X-100, 2 mM dithiothreitol, 2 mM phenylmethylsulfonyl fluoride, and
cOmplete protease inhibitor cocktail (Roche Cat. No.11836153001)). Cell suspensions
were sonicated three times for 30 seconds with 90% power on ice. Lysates were clarified
by centrifugation (20 minutes, 16,000 rcf) and the supernatant was bound to sonication
buffer equilibrated Glutathione Sepharose (GE Healthcare 17075601) for 2 hours at 4 ºC
with rotation. Resin was washed with 30 resin volumes of sonication buffer and GSTfusion proteins were eluted with 20mM Glutathione in sonication buffer. Eluted protein
was buffer exchanged into cleavage buffer (50 mM Tris HCl, pH 8.0, 100 mM NaCl, 1
mM EGTA, 1 mM DTT). To cleave GST moiety, 2 units Prescission Protease (GE
Healthcare 27-0843-01) were added for every 100 mg of eluted protein and incubated
for 4 hours at 4 ºC. The cleavage reaction was then incubated to cleavage buffer
equilibrated Glutathione Sepharose for 30 minutes to removed cleaved GST and
Prescission Protease, which is also GST-tagged. Elution fractions were pooled and
concentrated to 3 mg/ml.
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4.8 Ppz1 Phosphatase Assay
0.7 µM purified Ppz1 or Ppz1R451L was mixed with either 2.1 µM hexameric
Hsp104 or Hsp104A503S (purified as reported)(207) and 4 mM ATP (pH 7.5) in Buffer A
(20 mM Tris-HCl pH 7.5, 100 mM KCl, 5 mM DTT, 0.1 mM EGTA, 10% glycerol, 20µg/ml
BSA, 0.005% Triton X-100, 10 mM MnCl2). 10mM pNPP reagent was added, at the
concentration recommended in manufacturer instructions (BioAssay Systems Cat. No.
POPN-500). Absorbance at 405nm was measured every 30 seconds for 15 minutes by
Tecan Safire2 at room temperature.
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